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Abstract
Precise control over transcriptional regulation is required for normal cell function. Errors
in transcriptional regulation underpin many diseases including cancer. Thymine DNA
Glycosylase (TDG) is a base excision repair protein and a coregulator that has been
implicated in a diverse set of fundamental biological processes including embryonic
development, nuclear receptor signaling and Wnt signaling. Importantly, TDG has been
shown to play an important role in transcriptional regulation in a wide variety of systems.
Details surrounding the mechanism through which TDG acts remain unclear. In this thesis
I explore the role of TDG in Estrogen Receptor (ER)-dependent signaling and in cellular
senescence.
To characterize the role of TDG in ERα mediated signaling I first mapped β-Estradiol (E2)dependent DNA binding of TDG in the MCF7 breast cancer cell line using ChIP-Seq.
Using bioinformatics in conjunction with more traditional biochemistry techniques I
established that a significant component of TDG binding occurs at enhancers, where it was
able to mediate the production of enhancer RNA (eRNA) and 3-dimensional reorganization
of transcriptional units. Knockdown of TDG disrupts E2-mediated upregulation of ERtargets and inhibits growth. Remarkably, in addition to behavior mimicking that of an
oncogene, I find that TDG knockdown and depletion result in a much more aggressive
phenotype, revealing its role as a potential potent tumor suppressor.
To explore the role of TDG in cellular senescence I induced senescence in IMR90 human
fibroblasts using hydrogen peroxide (H2O2) and monitored markers of senescence,
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including proliferation and β-galactosidase staining. I found that while senescence was
readily inducible in this cell line using H2O2, knockdown of TDG was able to significantly
impede the process. Using ChIP, I found that TDG was recruited to a CpG island
overlapping the CDKN2A promoter, a tumor suppressor important for senescence. Further
studies including ChIP, bisulfite sequencing and conventional assays revealed that TDG is
required for H2O2-mediated transcription of CDKN2A in a CBP-dependent and activedemethylation independent manner.
Collectively, these studies extend the role of TDG in transcriptional regulation, implicating
it as a mediator of cellular senescence and as a mediator of eRNA transcription and 3dimensional re-organization in hormone signaling.

Keywords
Thymine DNA Glycosylase, Estrogen signaling, Senescence, Cancer, Enhancers, eRNA.
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Chapter 1.

Introduction
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1.1

Overview

Multicellular organisms are composed of a variety of cell types that perform specialized
functions critical to an organism’s survival. Diverse cell types within the same organism
often contain the same set of DNA yet can exhibit very different morphologies and
functions. This discrepancy is resolved by the observation that a cell’s phenotype is
controlled not by the set of genes it possesses, but rather by which genes are expressed:
transcribed into RNA and ultimately translated into protein. As such, cells of the same
“type” often share expression profiles that closely resemble one another but differ from
cells of a different type. Changes to a normal cell’s expression profile can result in changes
to its established function and morphology. When this occurs more generally, an
organism’s fitness can become impacted. For example, during embryonic development,
where cells progress from undifferentiated stem cells to differentiated cells with specific
functions, control of transcription is particularly critical and disruption to the
transcriptional program can result in developmental errors that can be lethal (Cortázar et
al., 2011; Cortellino et al., 2011; Li et al., 1992). Loss of transcriptional regulation and
subsequent disruption of expression patterns is also observed to underlie numerous
pathologies. A consistent feature found in many cancers is that the transcription of tumor
suppressors and oncogenes are often dysregulated (Bihl et al., 2012; Frietze et al., 2014;
Zheng and Blobel, 2010). Therapeutically, targeting defects in expression in order to reestablish ‘normal’ expression patterns has been used successfully to treat some diseases:
in the case of cancer these act primarily by silencing oncogenes or re-establishing
expression of some tumor suppressors (Morris and Chan, 2015). Building a deeper
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understanding of transcriptional regulation may provide insight into pathologies with an
underlying dysregulation of transcription.
An important component of transcriptional regulation are the coregulators which can
further be subdivided into “coactivators” and “corepressors”. Coregulators are proteins that
modulate transcription of DNA by controlling the transcriptional machinery’s accessibility
to the DNA. This is achieved either directly, by altering the chromatin structure through
covalent modification to the DNA and/or associated histones, or indirectly, acting as
scaffolds which then recruit other proteins that can then modify the chromatin. Thymine
DNA Glycosylase (TDG) is a coregulator that has been implicated in a diverse set of
fundamental biological processes including embryonic development, nuclear receptor
signaling and Wnt signaling. While TDG has been shown to regulate transcription in a
wide variety of systems, details surrounding its mechanism of action remain unresolved.
In this thesis I seek to extend our knowledge of transcriptional regulation by exploring the
role of TDG in different contexts. Specifically, I investigate TDG’s role in estrogen
receptor dependent signaling and in cellular senescence.

1.2

Eukaryotic Transcriptional Regulation

The establishment and maintenance of correct expression profiles is required by all
biological process from development to fully differentiated tissues. Deviations from
normal expression patterns are often observed in cells during disease development and can
be directly responsible for the pathological changes to a cell’s phenotype. Transcription of
DNA to its corresponding RNA and finally translation to the protein product is a highly
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regulated process with multiple checkpoints along the way.

Because it requires a

considerable investment of energy and resources, regulation during the initial stages is
much more efficient as it prevents the cell from unnecessarily wasting resources and
energy. One of the earliest points of regulation occurs during the transcription of DNA to
RNA. Control at the transcriptional level can be broadly categorized into 2 distinct, but
intimately related mechanisms: Transcription factor dynamics at regulator regions as well
as epigenetic control over accessibility to these regions.

1.2.1

Transcriptional Regulatory Regions

Transcription occurs through 3 distinct stages:
(1) Initiation - the localization and assembly of critical transcriptional machinery, RNA Pol
II and its auxiliary factors to the targeted gene’s regulatory regions.
(2) Elongation - The process whereby RNA Pol II transverses the DNA template and
assembles the RNA molecule.
(3) Termination – Dissociation of RNA Pol II from DNA template.
The initiation stage of transcription is a particularly important point of regulation as the
cell has not yet invested energy or resources at this point. During this stage, the
transcriptional machinery is typically localized to the gene’s regulatory regions, which
contain elements critical for its transcription. Transcriptional initiation requires the
formation of a “pre-initiation complex” (PIC) that consists of, at a minimum, RNA Pol II
(the enzyme responsible for synthesizing the RNA molecule from DNA template) and its
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6 general auxiliary factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH) (Luse, 2013).
The promoter, a region of DNA adjacent to the gene and often encompassing the
transcriptional start site, contains regions that facilitate the formation of this complex. The
promoter often contains a B recognition element (BRE), a downstream promoter element
(DPE) and the “initiator element” or a TATA box. Generally, the presence of the TATA
box and initiator element is mutually exclusive: promoters tend to have one, but not both,
of these elements. During transcriptional initiation, these highly conserved elements are
recognized and bound by auxiliary factors (either TFIID or TFIIB) which then results in
further sequential binding of the additional auxiliary factors and RNA Pol II itself, forming
the PIC. While the PIC is sufficient to produce minimal levels of transcription, in order to
achieve the levels that often observed in vivo, an additional class of molecules called
‘transcription factors’ must be recruited.

1.2.2

Transcription Factors

Transcription factors are proteins that regulate transcription at the point of transcriptional
initiation, by facilitating or inhibiting loading of the PIC (Petrykowska et al., 2008).
Conservative estimates put the number of transcription factors at approximately 1,300
(approximately 6% of the protein coding genes in the human genome) (Vaquerizas et al.,
2009). Transcription factors can be broadly classified into two mechanistic categories: (1)
General transcription factors which include RNA Polymerase II and its auxiliary factors
that form the pre-initiation complex and which are ubiquitously expressed in tissues and
(2) Sequence specific transcription factors which recognize and bind to specific sequences
of DNA and which are frequently expressed in a tissue-specific fashion.
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Structurally, specific transcription factors are often composed of multiple domains that
each serve distinct functions:
(1) DNA binding domain - a structural motif often composed of alpha helices, beta
sheets, and/or disordered regions that recognizes and binds specific DNA sequences
termed ‘response elements’ or ‘transcription factor binding motifs’. A DNA binding
motif can take many forms, for example the most common motifs include the helixloop-helix domain that is characterized by a simple structure of two α-helices linked by
a loop, the “zinc finger” domain, whose activity and structure requires the presence of
one or more zinc ions, as well as structurally more complex domains such as the
“winged-helix transcription factors” which are composed of four helices and a twostrand beta-sheet (Yusuf et al., 2012).
(2) Signal sensing domain – This domain allows transcription factors to respond to the
presence of endogenous or exogenous molecules by altering their activity and/or
localization. A well-studied example of this is the Estrogen Receptor α (ER), a nuclear
hormone receptor that underlies sexual and reproductive development in females. ERα
is found mostly in the cytoplasm under normal conditions (Putnik et al., 2012). Upon
binding β-Estradiol (E2), an ERα agonist, ERα molecules undergoes a conformational
change, dimerizing and translocating into the nucleus where they bind to “Estrogen
Response Elements”, a specific DNA sequence recognized by ERα and found in the
regulatory region of ER-target genes. Recruitment of additional factors follows ERα
binding, resulting in transcriptional upregulation of the ERα target genes (Carroll et al.,
2006; Hah et al., 2013; Welboren et al., 2009).
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(3) Transactivation domain – In order to significantly impact transcription levels of a
target gene, the recruitment of an additional class of proteins called “coregulators” is
often required. The transactivation domain is a series of amino acids that function as a
scaffold capable of recruiting certain coregulators. Both transcription factors and
coregulators can have multiple interaction domains that allow for each to interact with
multiple partners. For example, p53 contains two transactivation domains that are a
part of the “Nine Amino Acid Transactivation Domain” a family of transactivation
domains common to many eukaryotic transcription factors. This transactivation domain
interacts with specific protein binding domains including the “TAZ1” and “KIX”
domains which are both found on coregulators such as, CBP/p300. The interaction
between these domains and those of p53 is required for CBP/p300 recruitment and
activity at sites of p53 binding (Kasper et al., 2011; Lee et al., 2010).
Transcription factors can be regulated through transcriptional silencing and through posttranslational modifications that can either enable or prevent them from binding to their
respective response elements. This is important, as the transcription levels of a specific
gene are often dictated not by a single transcription factor, but rather by the collective
effects of the transcription factors bound to its regulatory region. Certain transcription
factors are only present in particular cell types, allowing those cells to respond to a
particular stimulus in a manner entirely distinct from cell types that expresses a different
set of transcription factors. This “combinatorial system” of transcriptional regulation
allows an organism to respond to a vast and diverse set of exogenous and endogenous cues,
while limiting the required genome size and the amount of transcription factors needed
(Reményi et al., 2004; Vaquerizas et al., 2009).

8

1.2.3

Coregulator-mediated regulation of chromatin

In eukaryotic cells, DNA is stored in a complex with protein and RNA called ‘chromatin’
(Figure 1-1). The fundamental subunit of chromatin is the nucleosome consisting of
approximately 147 base pairs (bp) of DNA wrapped around an octamer of positively
charged histone proteins containing two of each of H3, H4, H2A and H2B (Eickbush and
Moudrianakis, 1978). Nucleosomes are separated by short stretches of ‘linker’ DNA
approximately 80 bp in length. Chromatin at this level of organization is referred to as
‘euchromatin’ and when viewed under an electron microscope resemble ‘beads on a string’
(Figure 1-2) (Cann and Dellaire, 2011). The next level of organization involves “linker”
histone H1, a non-core histone protein that binds outside of the core nucleosome at the
location where the DNA enters/exits the nucleosome and that also interacts with the region
of linker DNA that connect histones. Histone H1 interactions stabilize the DNA into a
further compacted, “30nm fiber” (debate however still exists as to the specific structure
this fiber takes) (Cann and Dellaire, 2011). Chromatin at this level of organization is often
referred to as heterochromatin. Chromatin generally exists in a heterogenous state
composed of both euchromatin and heterochromatin, however during specific stages of the
cell cycle (i.e. mitosis/meiosis), chromatin is further compacted into chromosomes in
preparation for cellular division.
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Figure 1-1. Progressive levels of chromatin compaction.
Incorporation of linker histone H1 generally marks the transition from a euchromatin
(favorable to transcription) to heterochromatin (transcriptionally repressed state).
(With modification from source:
https://commons.wikimedia.org/wiki/File:Chromatin_Structures.png)
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Figure 1-2. Electron micrograph of ‘11nm chromatin fiber’.
Also referred to as “beads on a string” the chromatin in this state is composed of
nucleosome units (black brackets), that can be further resolved to nucleosomes (black
arrowhead) and DNA linker region (white arrowhead). (Original image by Chris
Woodcock, doi:10.7295/W9CIL709)
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Chromatin structure is inherently linked to transcriptional activity: the ‘relaxed’
organization of euchromatin readily allows the transcriptional machinery to gain access to
DNA and is therefore often found in regions that are transcriptionally active.
Heterochromatin, which is a highly compacted structure, masks the underlying DNA from
the transcriptional machinery, inhibiting access to general and most sequence specific
transcription factors, and is therefore often found associated with transcriptionally silent
areas of the genome. An exception to this is a class of transcription factors called ‘pioneer
factors’ which possess a certain structure that allows them to bind heterochromatinized
DNA. Once bound to DNA, transcription factors often recruit another class of proteins,
called ‘coregulators’, that dynamically alter the chromatin landscape, either making it more
or less permissible to transcription. Therefore, whether a transcription factor has a positive
or negative effect on transcriptional activity is often dictated by the coregulators it recruits.
Coregulators can alter the structure of chromatin primarily through two methods: (1) The
removal of nucleosomes through an ATP-dependent process, and/or (2) post-translational
modifications of histones. Post-translational modifications often occur in the form of
covalent addition of an acetyl, methyl or phosphoryl group to specific residues on
unorganized regions of the histone that protrude out from the nucleosome referred to as
histone ‘tails’ (Figure 1-3) (Eickbush and Moudrianakis, 1978). The addition or removal
of these modifications can alter the affinity between the DNA and histones which leads to
either a relaxing or tightening of the chromatin structure that, in turn, impacts transcription
levels. In the case of histone acetylation for example, addition of acetyl groups to specific
lysine residues on the histone tails neutralizes the positive charge on the histones disrupting
their affinity for negatively charged DNA.
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Figure 1-3. Histone tail modifications.
Schematic highlighting potential histone tail modifications that have been observed.
Generally, only a subset of these will be present on any one nucleosome. At any one
particular site acetylation and methylation can be found to be mutually exclusive, targeting
the same residue.
(Source: Wikimedia Commons. Author: Mariuswalter; Based on work from RodriguezParedes and Esteller, Nature, 2011)
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This weakened affinity promotes an ‘open’ chromatin state, encouraging transcriptional
machinery access.

Coregulators that catalyze this reaction, called histone

acetyltransferases, are therefore often referred to more specifically as “coactivators” as
their presence strongly corresponds to increased transcriptional activity. In contrast,
coregulators that contain histone deacetylase activity, remove acetyl groups from histones,
and therefore exert the opposite effect: they reestablish the positive charge on histones
which increases the affinity for DNA promoting a more organized chromatin structure that
is less accessible to the transcriptional machinery. Coregulators with histone deacetylase
activity are therefore often referred to as “corepressors” and are often found at
transcriptionally silenced genomic regions.
The relationship between histone methylation and transcription is more complex because
methylation of specific residues can correspond to either transcriptional silencing or
activation depending on the location and the abundance of methyl marks that are deposited.
For example, trimethylation of lysine 27 on Histone H3 (H3K27me3), which is catalyzed
by EZH2, a component of the polycomb repressive complex 2, is found exclusively at
transcriptionally silenced regions, while monomethylation of the same site (i.e.
H3K27me1) is strongly associated with active transcription (Barski et al., 2007).
Importantly, genomic regions contain numerous nucleosomes that are each composed of
multiple histones, and each histone has multiple sites that can be modified. While certain
histone modifications are strongly correlated with the expression or repression of any given
region, it is the specific permutation of histone modifications (i.e. the “Histone code”) that
best correlates with the coactivator composition at that region and its transcriptional status.
In addition to altering the affinity between the DNA and histones, addition or removal of a
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specific modification from a histone residue can also create binding sites for factors that
can recognize a particular modification or, conversely, mask such a site – further
complicating the effects that covalent modifications may have in any given context.

1.2.4

DNA Methylation and Active Demethylation

In addition to changes in the organization of chromatin, modifications to the DNA
molecule, primarily in the form of covalent modifications to cytosine, can have profound
effects on transcriptional regulation (Aran and Hellman, 2013). Cytosine can be covalently
modified primarily in a CpG context. DNA methylation patterns are maintained by DNA
methyltransferases (DNMTs) which recognize unmethylated/hemi-methylated DNA and
catalyze the transfer of a methyl group from S-adenosylmethionine (SAM) to the C5 carbon
of cytosine, creating 5-methylcytosine (5mC). Remarkably, while most CpG’s in normal
tissue are methylated, promoters often contain long stretches of CpGs (CpG islands) which
are maintained in an un-methylated state (Feltus et al., 2003). Hyper-methylation of these
promoters is strongly associated with transcriptional repression of the associated gene(s)
(Baylin and Herman, 2000). Mechanistically, 5mC can repress transcription either directly
by making regulatory sites inaccessible to transcription factor binding, or indirectly
through the recruitment of proteins that contain methyl-binding domains which in turn,
recruit additional proteins which have repressor activity.
Patterns of global methylation and promoter-specific hypomethylation are maintained in
healthy tissue (Baylin and Herman, 2000). However, in most cancers DNA methylation is
highly dysregulated consisting of global hypomethylation and promoter-specific
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hypermethylation. Global hypomethylation has been proposed to have an oncogenic effect
by activating epigenetically silenced transposable elements or endogenous viruses, as well
as increased rates of chromosomal rearrangements (Chen et al., 1998b). Furthermore, many
tumor-suppressor genes contain CpG islands in their promoters that are hypermethylated
in cancer and are transcriptionally silenced. Importantly, DNA methylation inhibitors can
reactivate epigenetically silenced tumor suppressors and have been used therapeutically
(Licht, 2015). While the mechanism governing DNA methylation has been extensively
researched and is well characterized, the mechanism(s) governing DNA demethylation
have proven to be more elusive.
DNA demethylation can occur through both active and passive pathways. The passive
pathway is achieved primarily through the loss of DNMT activity. In oocytes this is
achieved primarily through the exclusion of DNMT1 from the nucleus, while in primordial
germ cells this is achieved through the down-regulation of UHRF1, a protein that targets
DNMT1 to hemi-methylated DNA (Messerschmidt et al., 2014; Ratnam et al., 2002).
During proliferation, this inability to methylate DNA results in the gradual dilution of the
methylation signal over successive rounds of DNA replication. On average, cells would
theoretically retain 50% of the number of methylated CpG’s that the previous generation
had, meaning that after 9 cell divisions the retained percentage of methylation remaining
would be approximately 0.2% of the first generation’s methylation levels.
The first clues that an “active” demethylation process must exist came from the observation
that paternal DNA is almost entirely (80-90%) methylated prior to zygote formation, yet
it becomes entirely de-methylated shortly thereafter, prior to DNA replication
(Messerschmidt et al., 2014). Subsequent work has found that active demethylation is
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wide-spread occurring in brain as well as skeletal muscle and has been reported to occur in
response to extracellular signals such as TGFβ, retinoic acid, and fibroblast growth factor
1 (FGF1) (Bruniquel and Schwartz, 2003; Guo et al., 2011; Zhang et al., 2007).
While it was originally hypothesized that active demethylation occurs through direct
enzymatic removal of the methyl group from cytosine (as is observed in certain plant
species), no enzyme capable of this excision have been identified in human cells. Instead,
in mammalian systems, the removal of 5mC is dependent on a step-wise oxidation process,
catalyzed by members of Ten Eleven Translocation (TET) family of proteins. This
iterative oxidation process starts at 5mC and first generates 5-Hydroxymethylcytosine
(5hmC) which is then further oxidized by TET proteins to 5-Formylcytosine(5fC) and
finally to 5-Carboxylcytosine(5caC) (Ito et al., 2011). 5fC and 5caC are then cleaved by
TDG which, in a highly coordinate series of steps involving APE1 and members of the
Base Excision Repair pathway, re-establishes an unmodified cytosine at the site (Maiti and
Drohat, 2011) (figure 1-4).
Active demethylation has been primarily investigated in the context of promoters, where
TDG-dependent demethylation was required for expression of gene-target(s). However,
recent work in embryonic stem cells has found that TDG depletion results in the
accumulation of 5mC metabolites at distal enhancers (Song et al., 2013; Wheldon et al.,
2014). While methylation status of promoters strongly correlates with gene expression, an
analysis of 390 ER-positive breast tumors revealed that methylation of distal sites corelates
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Figure 1-4. Active demethylation pathway.
Recent studies have established that TET-mediated, iterative oxidation, followed by TDG
excision and BER is likely the most prevalent method through which active demethylation
is achieved in mammals.
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to target gene expression more closely than promoter methylation. The significance of this
remains to be elucidated and the exact role that TDG-mediated active demethylation plays
at enhancers in this context, remains unresolved.

1.2.5

Enhancers and enhancer RNA (eRNA)

In addition to proximal regulatory elements, regulatory regions can also be found large
distances away (up to millions of bases away or on different chromosome altogether) from
specific genes.

These regulatory regions, called ‘enhancers’, are able to mediate

transcriptional activity of associated gene(s) (Jeong et al., 2014; Li et al., 2013; Ong and
Corces, 2012; Yip et al., 2012).
Functionally, enhancers share some similarities with promoters and often contain binding
sites for transcription factors, RNA Pol II and components of the pre-initiation complex as
well as coregulators (Plank and Dean, 2014). Enhancers are often located in non-coding
regions of DNA and, in response to an activating signal, some enhancers are transcribed to
produce long non-coding RNA, termed ‘enhancer RNA’ (eRNA) (Lam et al., 2014; Li et
al., 2013; Pulakanti et al., 2013). While the role of eRNA still remains somewhat
controversial, recent studies have confirmed that eRNA production, per se, causes
conformational changes that bring the enhancer in direct contact with the target-gene
promoter (Li et al., 2013). This brings together transcription-factors, coregulators and
RNA-Pol II bound at the enhancer and the basal transcriptional machinery positioned at
the proximal promoter (figure 1-5). Disruption of either eRNA production or looping can
prevent transcription of the associated gene (Li et al., 2013).
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While conventional reporter/luciferase assays are still used to identify potential enhancers,
recent developments in high-throughput sequencing have allowed us to gain unprecedented
insight into their structure and function. Poised or active enhancers are often found in
‘open’ chromatin regions depleted of nucleosomes - allowing for transcription
factor/coregulator accessibility (Pulakanti et al., 2013). DNase-Seq and FAIRE-Seq are
both techniques which can identify nucleosome depleted regions by digesting accessible
DNA using DNase I or by depleting the histone-associated ‘closed’ regions, respectively.
Unfortunately, these techniques alone provide an incomplete picture, as not all open
regions are necessarily enhancers, and not all enhancers will necessarily be found in an
‘open’ chromatin state.
As identified by conventional biochemical techniques, enhancers are often sites of
transcription factor and coactivator binding (Frietze et al., 2012). This property has been
used to predict/identify potential enhancers by searching for genomic regions outside of
annotated gene’s that contain a cluster of transcription binding motifs or that contain a
sequence conserved between species. However, the location of clustered transcription
factor binding motifs or highly conserved sequence, does not necessarily mean that the
region is an enhancer, as many transcription factor binding motifs are not actually bound
by the transcription factor in vivo or are only bound by those TF’s in certain cells, or in
certain contexts. A more accurate way to identify/predict enhancer regions is through the
identification of certain coregulator binding sites (Shlyueva et al., 2014).
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Figure 1-5. Schematic of Enhancer and Promoter in 'active' configuration.
An example of a potential enhancer/promoter complex formed prior to release of Pol II and
transcription. The composition of components at enhancers differs depending on context,
however certain elements (Activators, coactivators, RNA Pol II, etc.) appear to be required.
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Because coregulators do not bind DNA directly (rather they are largely recruited by their
interaction with specific transcription factors), global ChIP-Seq targeting cofactors such as
the lysine acetyltransferase CBP (or its homologue p300) would identify regions that are
bound by both CBP/p300 and their interacting transcription factor, removing the noise from
the cruder motif analysis or sequence conservation studies. The binding of specific
coactivators or corepressors to enhancers often results in histone markings that indicate the
‘state’ of the enhancer. For example, acetylation of histone H3 on Lysine 27 (H3K27Ac)
is often found at enhancers and promoters that are actively being transcribed while
H3K4me1, on the other hand, is a mark that is often found at enhancers but not at promoters
(Bulger and Groudine, 2011; Lupien et al., 2008). Regions that contain both H3K27Ac
and H3K4me1, have been strongly associated with actively transcribed enhancers
(Creyghton et al., 2010; Zentner et al., 2011). Additionally, histone marks indicating
repressed states also exist. For example, H3K27me3 (Histone H3, Lysine residue 27, trimethylation) is often associated with transcriptional silencing and corresponds to the
presence of the Polycomb complex, a protein complex that mediates silencing of target
regions (Zentner et al., 2011). Collectively, the specific set of histone marks at an enhancer
are often able to accurately characterize its state (i.e. “poised”, “silenced” and “active”)
and are now widely used throughout enhancer related studies (Shlyueva et al., 2014).
Because enhancers are often transcribed into eRNA, which have been shown to play
functional roles in 3-dimensional re-organization, techniques that are able to directly assay
for these features are extremely powerful ways to identify or predict enhancers. Global
Run-On Sequencing (GRO-Seq) is an accurate way to identify regions of the genome
where RNA Pol II is actively engaged in transcription and has been used to identify
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enhancers which produce eRNA in response to stimuli (Li et al., 2013). Various techniques
exist which can be used to identify chromosomal conformation such as Chromatin
Interaction Analysis by Paired-End Tag Sequencing (ChIA-PET). ChIA-PET allows for
the capture of 3-dimensional interactions that occur at sites of a protein of interest. As
enhancers are often characterized by interaction with the promoter and transcription (of
both eRNA from the enhancer and mRNA from the gene-target), ChIA-PET performed
with RNA Pol II has been used to successfully identify regions which are bonafide
enhancers partaking in promoter interactions (Fullwood et al., 2009; Li et al., 2012).
Alone, or in combination, these techniques have allowed for the accurate identification and
mapping of enhancers globally.
Enhancers play a fundamental role in cell-specific transcriptional regulation and the
importance of enhancers in human biology is wide-spread.

During embryonic

development for example, where precise patterns of gene expression are required,
enhancers play a fundamental role in controlling the spatial and temporal transcription of
key modulators of embryonic development (Creyghton et al., 2010; Ong and Corces, 2012;
Zhu et al., 2012). Errors in enhancer sequence can lead to a predisposition to many common
diseases, including cancer. Global methylation studies examining the association between
methylation and gene dysregulation in cancer in fact found that the transcript level of genes
more strongly correlated to its enhancer methylation status than to the methylation status
of its promoter (Aran and Hellman, 2013; Wiench et al., 2011). A deeper understanding
of enhancer regulation may be useful for treatment of pathologies that are underpinned by
a dysfunctional regulation program.
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1.3

Thymine DNA Glycosylase (TDG)

TDG was originally discovered by protein purification of factors capable of binding and
processing T:G mismatches in HeLa cells (Neddermann and Jiricny, 1993). TDG is, a
member of the “Mismatch Uracil Glycosylase” (MUG) branch of the “Monofunctional
Uracil-DNA Glycosylase” (UDG) superfamily. Members of this family are characterized
by their ability to excise mismatched Uracils (G/T or G/U mispairs) from double-stranded
DNA. Structurally, TDG is composed of a catalytic ‘core’ flanked by N- and C- terminals.
All three of its domains contain binding sites that mediate its physical interaction with a
diverse set of proteins including components of the Base Excision Repair (BER), Nuclear
Receptors (NRs), as well as additional coregulators (Figure 1-6). Additionally, both the
N- and C- terminals are targets of post-translational modifications that have been shown to
alter the localization and activity of TDG (Hardeland et al., 2000; Hashimoto et al., 2013).

1.3.1

TDG - Glycosylase Activity and Function

While originally recognized as an enzyme capable of cleaving Thymine from T:G
mismatches, subsequent work has revealed that TDG is capable of accommodating and
processing a much broader set of substrates found at the cytosine position in a
cytosine:guanine (CpG) context (Cortázar et al., 2007).
The crystal structure has revealed that TDG’s catalytic domain forms a large hydrophobic
pocket capable of accommodating various adducts and derivatives of uracil and cytosine
including products resulting from oxidation, halogenation and deamination of these bases

29

and importantly, in the case of active demethylation, allows for the accommodation of the
5mC derivatives 5fC and 5caC(Maiti and Drohat, 2011; Raiber et al., 2012; Shen et al.,
2013).
The finding that TDG interacts with many transcription factors and coregulators suggests
that it can be targeted to specific sites through interaction with its binding partners
(Cortázar et al., 2007). Once localized to a site targeted for demethylation, TDG forms
specific interactions with the base being targeted for removal, a guanine adjacent to the
target site and importantly, the guanine opposite the base target for removal (Hashimoto et
al., 2013). The interactions between TDG and both guanines is of particular importance as
it allows for a control of specificity: interaction with the adjacent guanine confirms that
TDG is at a CpG site and interaction with guanine from the opposite strand confirms that
TDG is bound to double stranded DNA (Cortázar et al., 2007). These and other interactions
stabilize TDG at the targeted site and result in TDG intercalating with the DNA in place of
the targeted base, which is instead ‘flipped’ out of the double-helix and into the catalytic
site of TDG, ultimately leading to its cleavage (Hashimoto et al., 2013). Evidence for a 2nd
TDG molecule being present and taking part in the interactions has also been shown
(Cortázar et al., 2007). Cleavage of the mispaired base by TDG creates an abasic site which
is ‘nicked’ by Apurinic/apyrimidinic endonuclease (APE1). This process is highly
coordinated – once TDG cleaves the mispaired base, it notably binds the abasic site with a
high affinity.
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Figure 1-6. Schematic of TDG Protein.
Proteins known to interact with TDG are shown at approximate location where the
interaction is believed to take place. Regions known to be post translationally modified in
certain contexts are marked: Ac - Acetylation, S – Sumoylation.
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In order to ensure that the components required to carry out the next series of steps are
present, TDG dissociation from the abasic site requires both APE1 binding and
SUMOylation of TDG (Waters et al., 1999). The site is then repaired by DNA Polymerase
β and DNA ligase restoring an unmodified Cytosine at the site of repair.

1.3.2

TDG as a Coactivator

Evidence that TDG possesses functions independent of its glycosylase activity was first
demonstrated in studies investigating the role of TDG in CBP/p300-dependent
transcription (Tini et al., 2002). Using a combination of immunoprecipitation, reporter and
Avidin-biotin-coupled DNA assays, researchers demonstrated that TDG recruits and forms
a complex with CBP/p300, stimulating its transcriptional activity (Tini et al., 2002).
Importantly, inactivation of TDG’s glycosylase activity using a point mutation did not
affect its ability to bind or stimulate CBP/p300-dependent transcription, suggesting that
TDG may be behaving primarily as a coactivator.
Further evidence for the coactivator role for TDG has emerged from work in Estrogen
receptor signaling. ERα, a member of the nuclear receptor family that is responsible for
estrogen responsiveness in mammals and activation of ERα signaling has been implicated
in breast cancer progression. It has been shown that TDG forms a complex with the ERα
in response to ligand and localizes to ER-target promoters. Reporter assays directly testing
the role of TDG in E2-mediated signaling revealed that TDG is a critical mediator of ERsignaling and deletion of TDG inhibits transcription of ER-target genes. Importantly, a
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catalytically inactive mutant had no effect on TDG’s ability to mediate E2-transcription,
further supporting its a role primarily as a coactivator (Chen et al., 2003).
Similar observations have been made regarding TDG’s role in Wnt signaling. Wnt
signaling underlies many fundamental biological processes during embryogenesis and
importantly, is often dysregulated in cancers. In colorectal cancer (CRC) aberrant Wnt
signaling drives proliferation and progression of the disease (Xu et al., 2014). TDG forms
a complex with CBP and TCF4, a transcription factor critical to Wnt signaling that localizes
to Wnt-targets and potentiates Wnt-signaling. ChIP assays at c-myc, in conjunction with
shRNA-mediated depletion of TDG, revealed that TDG binding is concomitant with H3
acetylation (a function of CBP/p300) at the site which was not observed upon TDG
depletion (Xu et al., 2014). These findings suggest that TDG facilitates transcriptionally
favorable alterations to the chromatin environment through its recruitment of CBP/p300 to
Wnt targets. Similar to previous reports, a catalytically inactive mutant of TDG had no
effects on TDG’s ability to drive Wnt signaling, again supporting the notion that TDG’s
functionality is primarily that of a scaffold in certain contexts.
Further work characterizing the functional role of TDG has found using mouse knockout
models, where TDG knockout is embryonic lethal (Cortázar et al., 2011; Cortellino et al.,
2011). Interestingly, one group found that Tdg knockout mice exhibited phenotypes that
resembled both that of CBP/p300 null mice embryos as well as those deficient in select
RAR/RXR genes, suggesting that TDG deletion may disrupt CBP/p300-mediated and/or
retinoic acid signaling critical to proper development. TDG null mice have severe defects
in both CBP/p300 and RAR/RXR-dependent transcriptional activity. Furthermore, it was
shown that TDG is responsible for mediating the interaction between RAR/RXR and
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CBP/p300 and that deletion of TDG prevented CBP/p300 recruitment to RAR/RXR
targeted genes and also resulted in a loss of H3 acetylation(Cortellino et al., 2011; Hassan
et al., 2017). Work by a separate group found that in addition to disrupting CBP/p300
binding at known RAR/RXR sites, TDG deletion disrupted CBP/p300 recruitment at
various other loci important for development. In addition to disruption of CBP/p300
recruitment, TDG deletion disrupted recruitment of other important factors including
GADD45a, AID and MLL1(Cortázar et al., 2011).
Interestingly, disrupting the glycosylase activity of TDG in mouse models is also
embryonic lethal (Cortellino et al., 2011). While it is not entirely clear why this occurs,
TDG’s glycosylase activity has been previously shown to be important for mediating
RAR/RXR-mediated transcription. RAR/RXR target genes have been shown to have
methylated promoters to which TDG is recruited, suggesting that in cases whether active
demethylation of a promoter is required for gene specific transcription, TDG’s glycosylase
activity becomes essential.
Finally recent studies have shown that TDG is important for maintaining enhancers in a
hypomethylated state in embryonic stem cells (Raiber et al., 2012; Wheldon et al., 2014).
This is important as enhancers can be transcribed to produce long non-coding RNA and
importantly, these enhancer RNA’s can have functional effects on gene-targets, sometimes
hundreds of thousands of base pairs away. While TDG’s role in transcriptional activation
is well established at promoters, whether or not TDG plays a role in the transcription of
eRNA at enhancers has not yet been investigated.

Taken together, TDG’s role as a

coactivator plays a central role in its ability to mediate a diverse set of signaling pathways,
however the mechanism(s) remain unclear.
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1.4

Rationale

To expand the body of knowledge surrounding TDG I explored its role in two systems:
ERα mediated signaling in the context of the MCF7 breast cancer line, and cellular
senescence in the context of healthy tissue.
The steroid hormone receptor ERα is overexpressed in many breast cancers and is often
the target of endocrine therapies, such as tamoxifen. Importantly, TDG interacts with ERα
and potentiates its action in a ligand-specific manner (Chen et al., 2003). In the classical
mechanism of ERα function, ERα is found mainly in the cytosol and binding of ligand
causes a conformational change that is concomitant with ERα dimer formation and
translocation into the nucleus. Activated ERα can bind DNA directly through its interaction
with ERE’s, or the binding can be indirect and mediated through an interaction with various
transcription factors. Work focusing specifically on the TFF1/PS2 gene promoter, a wellstudied target of ER-mediated signaling, has found that, in addition to the recruitment of
ER, E2 treatment resulted in the recruitment of large number of proteins to the TFF1
promoter that includes histone acetyl transferases and histone methyl transferases, the
nucleosome remodeling complex SWI/SNF and general transcription factors (Métivier et
al., 2003, 2008). Experiments which examined the kinetics of cofactor binding revealed
that rather than binding simultaneously, the recruitment and release of coactivators was
both combinatorial and cyclical in nature, with certain “sets” of factors binding while
others released, repeatedly (Métivier et al., 2003). In addition to the previously mentioned
factors, the promoter of TFF1 underwent cyclical methylation/demethylation during
transcriptional activation. Importantly, the increase in methylation coincided with an
increased binding of DNMT1 while demethylation coincided with release of DNMT1 and
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binding of TDG. siRNA mediated depletion of TDG resulted in an inability to effectively
remove the methylation and prevented TFF1 transcription (Métivier et al., 2008). The
cyclical methylation and demethylation is concomitant with binding of various cofactors
and chromatin remodelers, including TDG. Remarkably, knockdown of TDG using siRNA
resulted in a hypermethylation of the promoter and the inability to induce TFF1 using E2,
highlighting its critical importance in ERα signaling.
Recent high-throughput studies have provided a more global picture of E2-dependent ERα
binding. One surprising result from these studies was that a substantial portion of ERα
binding occurred at distal regulatory regions containing histone modifications that mark
enhancer sites (H3K27ac and H3K4me1). Studies employing GRO-Seq, which identifies
nascent transcription genome-wide, found that ERα was localized to the enhancers of
approximately ~90% of genes that showed upregulation in response to E2 (in contrast to
only ~9% that showed binding of ERα at their promoters) (Li et al., 2013).
While enhancers are often located in non-coding regions, in response to E2 the majority
(~83%) of enhancers associated with E2-regulated genes are transcribed. At the time it was
unclear whether transcription of eRNA was transcriptional noise due to the presence of
RNA Pol II or played a functional role. However recent studies have shown that eRNAs
per se may be required for target-gene transcription in different contexts (Hsieh et al., 2014;
Li et al., 2013; Melo et al., 2013). ChIA-PET is a technique capable of identifying longdistance chromatin interactions. These studies revealed that in response to E2, chromatin
rearrangement surrounding ER-dependent genes occurred by bringing into proximity
target-gene promoters with enhancers, which often times contain transcription factors,
coregulators and RNA Pol II, potentiating transcription of the target gene. Importantly,
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eRNA production at enhancers was shown to mediate this looping (Li et al., 2013). While
the mechanism through which eRNA regulates 3-dimensional re-organization is still
unclear, eRNA has been shown to directly recruit chromatin coactivators that may take part
in promoter-enhancer complex formation (Bose and Berger, 2017).
Generally, eRNA production often occurs at enhancers that are TET occupied and
hypomethylated (Pulakanti et al., 2013). This is interesting, as recent work in mouse
embryonic stem cells has shown that TDG localizes to enhancers and functions to maintain
them in a hypomethylated state. Furthermore, eRNA production drives 3-dimensional
reorganization that mediates ER-dependent transcription and I have recently found that
TDG mediates similar 3-dimensional reorganization during RAR signaling (Hassan et al.,
2017). While TDG’s ability to regulate ERα signaling has been established through
reporter assays as well through targeted assays at specific genes (i.e. TFF1), its role
globally remains to be explored.
The second component of my research focuses on the role of TDG in cellular senescence.
Senescence is a state of persistence cell-cycle arrest that occurs when cells have exceeded
their proliferative capacity. Proliferative senescence is a complex damage response
mechanism resulting from telomere depletion and causes an upregulation of cell-cycle
inhibitors and down regulation of pro cell-cycle signals(Rayess et al., 2012). In addition
to exceeding proliferative capacity, cells can be induced to senesce by exposure to ultraviolet radiation, oxidative stress as well as oncogene expression. The senescence program
is a critical barrier to cancer. Senescing cells have distinctive features that distinguish them
from their healthy counterparts. Most obvious is a distinct, flattened, morphology and an
enlarged cytoplasm. These cells will stain blue when exposed to X-gal under acidic
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conditions due to an enlarged lysosome cavity and abundance of beta-galactosidase
enzyme (Kurz et al., 2000). Transcriptionally, senescing cells often overexpress the tumor
suppressors p53, p21, ARF and CDKN2A (Chen et al., 1998a).
CDKN2A and ARF are potent tumor suppressors that are found at the INK4 locus (in
conjunction with a third tumor suppressor CDKN2B and the long non-coding RNA,
ANRIL).

Importantly, the transcription of gene-products at this locus sensitive to

epigenetic regulation: Specifically, methylation of their promoters. In many cancers the
promoters of these genes are hypermethylated, and demethylation causes re-expression.
For example, CDKN2B transcription, which is silenced through promoter methylation, can
be activated by TGFβ which, in certain contexts, removes promoter methylation
(Thillainadesan et al., 2012). Importantly, TDG has been shown to be a critical component
of the active demethylation process at this promoter, and loss of TDG results ablates
TGFβ’s ability to induce demethylation of the CDKN2B promoter and its transcription.
Similarly, reporter assays have revealed that when CDKN2A is hypermethylated, TDG is
required for its active demethylation and expression(Hu et al., 2010).

1.5

Objectives

To investigate the mechanism through which TDG regulates transcription, I treated the
MCF-7 breast cancer cell line with E2, an ERα agonist, and performed ChIP-Seq using an
antibody specific for TDG to map the locations to which it localizes (Chapter 2).
Bioinformatic analysis was performed to characterize (A) the binding sites of TDG genome
wide relative to genomic annotation (B) the overlap between ERα and TDG (C) the overlap
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between known transcription factors from the ENCODE database and (C) the histone
marks at these sites. Based on this analysis I hypothesize that in response to E2 TDG
regulates ER-target gene transcription through its recruitment to enhancers where it
mediates the transcription of eRNA and 3-dimensional organization.

To test the

hypothesis, I performed siRNA mediated knockdown experiments in conjunction with
real-time qPCR at both target-gene mRNA levels and enhancer eRNA levels from the same
set of ER-target genes. Chromosome Conformation Capture (3C) was performed at
GREB1, a well-studied ERα target gene, to determine whether TDG impacted 3dimensional organization. Finally, using both siRNA-depletion and CRISPR-knockout
cells, I investigated and characterized the role of TDG in proliferation, adhesion, migration
and invasion in the context of MCF-7 breast cancer cells.
In chapter 3, I investigate the role of TDG in senescence in the context of development and
in human adult fibroblasts. To determine the role of TDG in senescence I depleted human
lung fibroblasts of TDG using siRNA and treated them with sublethal, senescenceinducing, levels of hydrogen peroxide and monitored proliferation using growth curves and
CDKN2A induction using western blotting. To delineate a potential mechanism through
which TDG regulates CDKN2A, I interrogated the methylation status of the CDKN2A
promoter and performed ChIP using an antibody specific to CBP in the presence and
absence of H2O2.
TDG knockout is embryonic lethal, with mice dying at approximately E11.5. Interestingly,
recent work has revealed that during development in mice a highly regulated senescence
program is initiated, and specific structures being undergoing senescence around the time
knockout TDG mice die. As no previous study has been published examining the role of
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TDG in developmental senescence, I generated TDG knockout embryo’s and performed
beta-galactosidase staining and conducted a double-blind study to determine whether TDG
is important for execution of the embryonic senescence program in mice. Finally, to
identify genes affected by TDG knockout I performed RNA-Seq and bioinformatic analysis
on wildtype and TDG KO embryos.
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Chapter 2. Genome-wide Analysis Reveals a Role
for TDG in Estrogen Receptor-mediated Enhancer
RNA Transcription and 3-Dimensional
Reorganization.
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2.1

Introduction

Steroid hormones such as 17β-estradiol (E2) coordinate complex gene programs and exert
profound effects on cell growth, development and homeostasis(Farooq, 2015).

E2

mediates its biological effects by binding to, and activating, the estrogen receptor (ERα
and ERβ). The ERs are members of the nuclear hormone receptor superfamily which
function as ligand-activated transcription factors. In the classical mechanism of hormone
action, E2 binding induces receptor dimerization which facilitates binding to genomic
DNA at specific sequences in the regulatory region of ERα responsive genes called
“estrogen response elements”. Importantly, ligand-bound ERα undergoes a conformational
change that facilitates the recruitment of coactivator proteins that coordinate specific
transcriptional responses.
Genome-wide studies using ChIP-based technologies have shown that the majority of ERα
binding sites in breast cancer cells are found distally from gene promoters, and a significant
component are found within gene-specific “enhancer” regions in response to E2 (Jin et al.,
2015). Enhancers are essential regulatory regions found in non-coding regions that control
temporal and tissue-specific gene expression. Furthermore, given that less than 2% of the
mammalian genome accounts for protein-coding genes, an increasing number of mutations
and aberrant methylation patterns associated with breast cancer have been found to reside
in enhancer regions (Aran and Hellman, 2013). In addition to recruiting specific
transcription factors enhancers also bind specific coregulators and components of the
transcriptional machinery, including RNA polymerase II. Importantly, some enhancers are
actively transcribed into long non-coding RNAs known as enhancer RNAs (eRNAs)(Li et
al., 2013). While the exact role of eRNAs remains controversial, some eRNAs have been
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shown to regulate gene expression by causing a 3-dimensional conformational change
bringing together the promoter, enhancer, and transcriptional machinery into
‘transcriptional pockets’ (Hsieh et al., 2014; Li et al., 2013). It has been shown that E2
rapidly increases eRNA production at many sites of ERα binding and results in the
activation of adjacent genes (Li et al., 2013). Although the exact mechanism governing
eRNA transcription is unclear, recent evidence suggests that enhancer methylation status
may play a role in eRNA production (Pulakanti et al., 2013).
DNA methylation occurs at the C5 position of cytosine (5mC) and is found primarily in a
cytosine-guanine (CpG) context. Genome wide patterns of CpG methylation are deposited
by the DNA methyltransferases (DNMTs) and are important for the establishment of
proper chromatin states that are associated with normal development and cellular
homeostasis (Smith and Meissner, 2013). 5mCs function as targets for methyl-binding
domain proteins which can subsequently recruit additional chromatin remodelers and corepressors (Moore et al., 2013). Furthermore, in a promoter context, methylated CpGs can
render the site inaccessible to the transcriptional machinery resulting in transcriptional
silencing. Interestingly, while the majority of genomic DNA is methylated at CpGs
(Ehrlich et al., 1982), 40-70% of gene promoters contain long stretches of CpG clusters
(CpG islands) that are unmethylated based on bisulphite sequencing analysis (Saxonov et
al., 2006). This pattern of global hyper-methylation and promoter hypo-methylation is
present in healthy tissue and in differentiated cell types. Importantly, improper control of
the setting and erasure of these marks has been implicated in various pathological
phenotypes, such as cancer and abnormal embryogenesis (Baylin and Herman, 2000; Haaf,
2006).
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Whereas the mechanism of DNA methylation is well understood, a unifying mechanism
for DNA demethylation has not been unequivocally identified. DNA demethylation may
occur passively when newly synthesized DNA strands remain unmethylated during
successive rounds of DNA replication, as a result of DNMT1 inhibition. In contrast, active
demethylation is a replication-independent process involving the DNA glycosylase
Thymine DNA glycosylase (TDG).

In one scenario, cytidine deaminases such as

activation-induced deaminase (AID) or Apolipoprotein B mRNA editing enzymes
(APOBEC 1-4) convert 5mC to thymine, generating a G:T mispair (Suspène et al., 2005).
Excision of mispaired thymine by TDG initiates the base excision repair pathway (BER)
which effectively restores unmethylated cytosine.

However, this model has been

challenged recently because AID/APOBEC members are much less active on 5mC and its
derivatives in vitro and in vivo (Nabel et al., 2012). A more plausible mechanism involves
the Ten Eleven Translocation (TET 1-3) enzymes which oxidize 5mC to 5hydroxymethylcytosine (5hmC). Subsequently, 5hmC is then metabolized further by TETs
into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et al., 2011). These
oxidized 5mC metabolites, 5fC and 5caC, are recognized and removed by TDG
(Hashimoto et al., 2013; Maiti and Drohat, 2011). In addition, an alternative mechanism
has been postulated for ER-dependent demethylation in breast cancer cells(Periyasamy et
al., 2015). ER-dependent transcriptional activation at the TFF1 promoter requires cyclic
patterns of methylation and demethylation, that is mediated by recruitment of TDG in
concert with DNMT 3a and 3b (Métivier et al., 2003, 2008). It has been postulated that
Dnmt3a/b in addition to catalyzing de novo DNA methylation, can facilitate demethylation
by deaminating 5mC when SAM levels are limiting (van der Wijst et al., 2015).
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The generation of TDG knockout mice has corroborated the importance of TDG in
regulating active demethylation and tissue specific gene expression. Deletion of TDG in
the germline is embryonic lethal and leads to DNA hypermethylation and defects in the
expression of various developmentally regulated genes (Cortázar et al., 2011; Cortellino et
al., 2011) Additionally, 5fC and 5caC levels increase five to ten fold genome wide in TDG
null ES cells (Wu et al., 2014), (Song et al., 2013). TDG has also been implicated in
transcriptional control and gene expression by functioning as a molecular scaffold protein.
TDG interacts directly with ERα in a ligand dependent manner and co-localizes to the
promoter of TFF1 (Chen et al., 2003) resulting in increased gene expression, effects which
are lost when TDG is depleted (Métivier et al., 2008). TDG also interacts directly with
other transcription factors and coregulators and in TDG null MEFs, the presence of TDG
is required for recruiting the acetyltransferases CBP/p300, TET2 and other histone
modifying enzymes to a subset of target genes (Cortázar et al., 2011; Cortellino et al., 2011;
Hassan et al., 2017; Tini et al., 2002). These findings are consistent with the notion that
TDG plays a central role in epigenetic stability and methylation control.
In this study, I generated a global profile of TDG binding in MCF7 breast cancer cells in
response to E2 treatment using ChIP-Seq. I have integrated the data from our ChIP-Seq
assays with data from other genomic assays to provide a global view of TDG binding. In
response to E2 treatment, I show that TDG binds primarily to genomic regions upstream
of target genes which, in addition to recruiting ERα and RNA Polymerase II, also bind
various transcription factors, co-regulators and epigenetic modifiers including p300,
GATA3 and Tcf7l2 and are marked by histone marks indicative of active enhancers.
Importantly, TDG binds to regions which, in response to E2, transcribe eRNAs and take
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part in 3-dimensional restructuring of the genome. Remarkably, at a subset of enhancers
that E2 targets, I found that TDG depletion abrogates E2-mediated eRNA, disrupts 3dimensional reorganization at ERα targets such as GREB1 and disrupts E2-mediated
transcription of corresponding ER-target genes. To investigate whether TDG plays a
functional role in E2 signaling in breast cancer, I engineered an MCF7 TDG-knockout cell
line using CRISPR technology and found that TDG knockout and depletion leads to defects
in E2 mediated proliferation and sensitizes MCF7 cells to the anti-estrogen, tamoxifen.
Importantly, I also find that TDG depletion causes adhesion defects and drastically
increases the migratory capacity and invasiveness of MCF7 cells. Collectively our findings
suggest that TDG plays a central role in mediating the transcriptional and functional effects
of E2 in breast cancer and may prove to be an effective therapeutic target.

2.2
2.2.1

Results
Global TDG binding in response to E2

Previous reports have shown that, in response to E2, TDG physically interacts with ERα
and localizes to TFF1/PS2, a well characterized ER-target gene(Métivier et al., 2008). To
determine whether colocalization of TDG and ERα extends to other genomic locations,
MCF7 cells were treated with 100 nM E2 for 45min and ChIP-Seq was performed using a
TDG-specific antibody. Biological replicates were performed and for each replicate the
reads were processed to remove duplicates and corrupted reads before being mapped to the
human genome (hg19). Areas of significant enrichment were identified using an FDR 0.01.
To identify only high confidence peaks, the peak set was filtered and only those peaks with
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a p-value < 0.05 and fold-change greater than 1.2-fold were retained. Finally, by retaining
only peaks which appeared in both biological replicates I was able to identify 117 highlyconfident regions to which TDG localized in response to E2. Validations were performed
using conventional ChIP-qPCR (Figure 2-1A). Compared to genomic background, global
analysis of the high-confidence TDG peaks revealed that E2-dependent TDG binding was
enriched at promoters (7% of total TDG peaks, compared with 3% genomic background)
as well as distal to promoters with approximately 60% occurring intergenically (compared
to 52% for background) (Figure 2-1 B). However, overlapping TDG peaks with sites of
E2-dependent ERα localization revealed that 45% of TDG peaks occur at the same sites
where ERα localizes in response to E2 (Figure 2-1 C and D).
Recent studies have shown that the ERα is found at enhancers and colocalizes with various
transcription factors known to play important roles in enhancer regulation (Nguyen et al.,
2014). The publicly available database, “Transcription Factor ChIP-Seq Uniform Peaks”
from ENCODE contains the binding profiles of these and other transcription factors from
numerous cell lines. I compared E2-dependent TDG binding to the 690 files available from
ENCODE using two measures of similarity: Jaccard statistic and the Fisher exact test.
Within the ENCODE datasets, those which most closely resemble E2-dependent TDG
binding are the datasets from experiments recording ERα binding in response to E2
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Figure 2-1. Global analysis of E2-dependent TDG localization.
(A) MCF7 cells were treated with 100nM of E2 (45min) and ChIP-qPCR was performed
using TDG antibody. Region used as negative control shows low level of TDG binding in
ChIP-Seq data with no change in levels after E2 treatment. (*p-value < 0.05, error bars
represent standard deviation of the mean, n>2). (B) Sites of E2 dependent TDG binding
were mapped to the annotated genome using CEAS (C) Venn diagram showing overlap
between E2-dependent TDG peaks and ERα peaks obtained from public dataset. (D) Sites
of ERα binding (-/+ 1000bp) overlaid with TDG binding signal, showing strong
relationship between location of TDG binding and ERα binding at these regions.
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treatments in breast cancer cells such as MCF7 cells and the metastatic T-47D breast cancer
cell line. The other transcription factors that exhibit binding patterns most similar to that
of TDG are p300, GATA3, Tcf7l2, the oncoprotein ZNF217, and RNA polymerase II
(Figure 2-2A and B). Importantly, these proteins have been identified as having important
roles at enhancers. Interestingly, I also observe higher similitude between TDG and both
Myc and E2F1. While both proteins have been implicated in breast cancer progression,
little is known concerning their respective roles at specific enhancers. Motif analysis
focusing on TDG peaks that overlap with ERα revealed an enrichment for the canonical
Estrogen Response Element motif, as well as the GATA DNA binding motif (Figure 22C). In contrast, TDG peaks that do not overlap with ERα are enriched for only a single
motif, PU.1. Transcription factors from the GATA family regulate genes that are
implicated in cell cycle arrest and cell survival (Zheng and Blobel, 2010). GATA3,
specifically, has been identified as a critical component of mammary epithelial cells
development and is 1 of 3 genes that have been shown to be mutated in >10% of breast
cancers (Theodorou et al., 2013). Furthermore, GATA3 has been shown to mediate
enhancer accessibility in MCF7 cells and its depletion results in an altered binding profile
of ERα upon E2 treatment, with a corresponding altered change in target gene expression
(Theodorou et al., 2013).
Distal regulatory sites involved in gene repression or activation are frequently marked by
specific histone modifications. Enhancers involved in transcriptional activation high levels
of H3K27Ac, H3K4me2 and H3K4me3 (Chen et al., 2015; Creyghton et al., 2010; Lupien
et al., 2008) while sites involved in silencing are often devoid of most of these marks and
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instead contain H3K9me3 and H3K27me3 (Zentner et al., 2011; Zhu et al., 2012). To gain
a better understanding of the epigenetic makeup of sites to which TDG localizes in
response to E2, I compared our data with that of publicly available ChIP-Seq datasets
performed using antibodies against histone modifications. Aggregate plots and heatmaps
at sites of TDG, or TDG and ER, localization in response to E2 revealed that TDG localizes
with histones containing marks found at active enhancers (H3K27Ac, H3K4me2 and
H3K4me3) and depleted almost entirely of histone markings corresponding to repressed or
silenced enhancers (H3K9me3 and H3K27me3) (Figure 2-2D and E).
To determine the extent of overlap of TDG and the transcription factors identified in our
global analysis, I cross-referenced genes whose transcription is induced upon E2 treatment
with genes that are adjacent to TDG peaks (-/+ 100kb) to identify E2-inducible genes that
are potentially regulated by TDG. A subset of genes meeting these criteria were selected
and a closer examination of the genomic landscape surrounding sites of TDG was
performed (Figure 2-3). Remarkably, I find highly-enriched binding occurs precisely at
sites which bind the transcriptional factors identified in our original ENCODE analysis.
Furthermore, these sites of E2-dependent TDG localization are enriched for histone marks
that correspond to active enhancer while being devoid of marks corresponding to
repressed/silenced enhancers, predicted by our previous bioinformatic analysis (Figure 22D and 2-2E). I also found a basal-level of TDG binding across the DNA at these regions
which is likely reflective of TDG’s non-specific DNA binding activity.
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Figure 2-2. TDG localizes to sites occupied by transcription factors.
(A) Individual datasets obtained from the Transcription Factor ChIP-Seq Uniform Peaks
dataset from ENCODE were compared to the TDG dataset using the Fisher exact test pvalue and Jaccard statistic to determine relative similarity. A subset of the most similar
matches is labelled with the cell type and treatment, if disclosed, in brackets (B) Overlap
between TDG peaks and the corresponding ENCODE dataset (The average binding profile
of the 10 least similar datasets from the ENCODE database was used as controls. None of
the 10 least similar had more than a single peak which overlapped with our dataset). (C)
Motif analysis performed on sites of E2 mediated TDG localization revealed the canonical
estrogen response element (ERE) as a top hit followed by GATA protein consensus binding
site. (D) Overlap of ChIP-Seq signal from publicly available histone datasets at sites of E2dependent TDG binding in MCF7 cells. (E) Heatmaps showing intensity of histone marks
at sites of TDG binding. Sites where TDG localizes in response to E2 are enriched for
histone marks indicating ‘active’ enhancers (H3K27Ac, H3K4me2 and H3K4me3) while
depleted for those marking ‘repressed’ enhancers (H3K9me3 and H3K27me3).
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Figure 2-3. Transcription factor binding and histone modifications at a subset of
TDG-targeted genes.
Genomic regions surrounding genes identified as having E2-dependent TDG binding and
increased transcription show precise overlap of TDG, ERα and a subset of ENCODE
transcription factors. Additionally, overlap with datasets containing histone ChIP-Seq data
reveals the enrichment of histone marks corresponding to active/poised enhancers and
depleted of those marking repressed/silenced enhancers (SM = standard media).
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2.2.2

TDG depletion disrupts E2 mediated transcription of ERα
target genes

Due to its role as a transcriptional co-activator, I sought to determine whether genes to
which TDG binds, in response to E2, are up- or down-regulated. To address this, I
identified genes adjacent to TDG binding sites and then obtained their transcriptional
response to E2 from publicly available data (Putnik et al., 2012). I find that genes which
are differentially expressed in response to E2, and to which TDG localizes, are most often
up regulated and the magnitude of change is significantly higher in genes that are
upregulated when compared to those that are down regulated (Figure 2-4A and B). To
determine whether TDG is critical to the E2-dependant changes in expression, I first treated
MCF7 cells with siRNA targeting TDG and immunoblotted for TDG and ERα to ensure
ERα levels remained stable during TDG depletion. I then treated MCF7 cells previously
treated with scrambled siRNA or siRNA targeting TDG with 100 nM E2 for 1hr and
measured mRNA levels of a subset of target genes using qPCR. Remarkably, I find that
TDG depletion does not affect levels of ER, yet significantly reduces E2-mediated increase
in the transcript levels of all ERα dependent target genes tested. (Figure 2-4C and D). A
look at the top 10 genes that bind both TDG and are expressed upon E2 treatment reveals
a slight correlation between magnitude of TDG binding and gene expression (Figure 24E).
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Figure 2-4. TDG is required for E2 dependent gene expression.
TDG peaks were mapped to genes using GREAT software and cross-referenced with
publicly available MCF7 E2-dependant expression data. (A) Most genes associated with
TDG binding undergo up-regulation in response to E2 and (B) the fold-change experienced
by up-regulated genes in response to E2 is greater in magnitude than the fold-change
experienced by down-regulated genes (box-and-whisker plot). (C) Western blot of TDG
and ERα levels after treatment with scrambled siRNA (siControl) or siRNA targeting TDG
(siTDG) (left panels). (D) To determine whether TDG was important for transcriptional
upregulation of these genes, siControl or siRNA targeting TDG were treated with 100 nM
E2 for 1h. Analysis of mRNA levels using qPCR revealed that loss of TDG decreases, and
in some cases completely abrogate, E2-mediated transcription (n=3, p-value < 0.05). (E)
Comparison of E2-mediated TDG binding at genes which also experience the greatest
increase in E2-mediated transcription (Spearman coefficient shown).
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2.2.3

TDG is required for eRNA production

Recent studies using Global Run-On Sequencing (GRO-Seq) characterized nascent
transcription in response to E2 treatment in MCF7 cells and showed that many of the ERα
bound enhancers bind RNA pol II and transcribe enhancer RNAs (eRNA)(Li et al., 2013).
Importantly, eRNA transcription and/or eRNA transcripts per se are required for activation
of adjacent target genes(Li et al., 2013). To determine whether TDG plays a role in eRNA
transcription, I first looked too see whether sites of TDG binding coincide with sites of E2mediated eRNA transcription in MCF7 cells by overlaying sites of E2 dependent TDG
localization with publicly available GRO-Seq data. I find that, on average, sites of E2dependent TDG localization also undergo a concomitant increase in transcription in
response to E2 (Figure 2-5A and B). Furthermore, sites of TDG binding at the enhancers
of target genes I examined previously, overlap precisely with locations that undergo
transcription at those targets (Figure 2-5C). Transcription of non-coding RNA from ERtargeted enhancers is readily induced by 100 nM E2 treatment for 1hr. Remarkably,
depleting TDG protein using siRNA prior to treatment abrogates the ability of E2 to induce
eRNA from TDG-targeted enhancers (Figure 2-5D). These findings reveal for the first time
a potential mechanism by which TDG regulates ER-signaling.
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Figure 2-5. TDG depletion impacts eRNA production.
(A) Publicly available GRO-Seq data looking at levels of transcription at sites of E2dependent TDG binding reveals that sites of TDG binding experience increase in
transcription in response to E2 (a set of random peaks reflecting precisely the size
distribution of actual TDG peaks was used as control). (B) Heatmap of nascent
transcription using publicly available GRO-Seq data at sites of TDG -/+ E2. (C) E2 effects
on localization of TDG and ER, as well as transcription response, at specific targets. (D)
To determine whether TDG is required for eRNA production, MCF7 cells were depleted
of TDG using siRNA and transcript levels were measured in response to 100nM of E2 (1h)
(qPCR, p-value < 0.05).
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2.2.4

TDG is required for 3D conformational changes

Recent work in both ERα and androgen-receptor mediated signaling has revealed that
eRNA transcription and/or eRNA transcripts facilitate 3-dimensional re-organization of the
genome bringing the enhancer regulatory region into proximity with the promoter and
activating optimal target gene transcription (Hsieh et al., 2014; Li et al., 2013). Chromatin
Interaction Analysis by Paired-End Tag sequencing (ChIA-PET) is a technique used to
capture and quantitate long-range chromatin interactions that occur in the presence of a
protein of interest. By comparing ER-dependent TDG binding to data obtained from ChIAPET looping that occurs at sites of ERα binding in MCF7 cells, I find that a large
component of E2-mediated TDG binding occurs precisely at genomic sites that are
involved in the interactions between promoter and enhancer (Figure 2-6 A and B). Previous
groups have reported that eRNA production at GREB1 is a critical mediator of long-range
looping and targeted eRNA degradation is itself enough to attenuate looping and enhancercomplex formation at this gene (Figure 2-6C) (Li et al., 2013). Based on our findings that
TDG depletion inhibits E2 driven production of eRNA at GREB1, I predicted that TDG
depletion may negatively impact the long-range loop formation. To explore this possibility,
I induced formation of looping at GREB1 by treating cells with 100 nM E2 for 1hr after
siRNA-mediated depletion of TDG. Similar to previous reports I find that E2 is able to
induce the formation of the enhancer-promoter loop at GREB1. Remarkably, ERα
continues to be recruited to enhancer in the absence of TDG (Figure 2-6D), but 3D
reorganization is abrogated when TDG is depleted, highlighting TDG’s impact not only on
eRNA production but also on 3-dimensional chromosomal rearrangement (Figure 2-6E).
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Figure 2-6. TDG peaks overlap with sites involved in promoter-enhancer looping.
TDG binding was compared to public datasets containing E2-dependent ERα localization
and ChIA-PET performed using an antibody against ERα. (A) Heatmap showing ChIAPET signal at sites of TDG binding (left) and aggregate plot showing global average (right).
(B) Overlap of TDG, ER, and ChIA-PET signal at specific sites reveals TDG, ERα and
looping occur at precisely the same locations at these sites. (C) Schematic of GREB1
showing approximate locations of looping as identified by publicly available data. (D)
ChIP using ERα in the presence and absence of TDG as well as – or + E2, showing that
ERα binding is unaltered during depletion of TDG. (E) Loss of TDG prevents enhancerpromoter looping at the GREB1 locus. MCF7 cells were treated with siControl or siTDG,
and then treated with 100 nM E2 for 1hr. 3C, semi-quantitative method of measuring the
looping between the GREB1 enhancer and promoter, revealed that E2 driven looping of
the enhancer and promoter is disrupted upon TDG knockdown.
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2.2.5

Methylation status is not impacted by TDG knockdown

Recent studies have shown that the 5mC derivatives 5caC and 5fC, generated during
active demethylation, accumulate at ‘open’ enhancers in TDG knockout MEFs (Raiber et
al., 2012; Song et al., 2013) suggesting that active demethylation may be important for
eRNA production. Comparing sites of E2-dependent TDG binding with publicly available
bisulphite sequencing and DNase data revealed that while TDG binding coincides with
‘open’ genomic regions, the CpG’s are not methylated and the regions are in an ‘open’
state (Figure 2-7A-C) (Menafra et al., 2014). Bisulfite sequencing is unable to distinguish
between unmethylated cytosine and 5fC/5caC. To obtain a clearer picture of what impact
E2 signaling and TDG may have on 5mC derivatives at enhancers, I performed Methylaseassisted bisulfite sequencing (MAB-Seq). MAB-Seq consists of pre-treating genomic DNA
with the bacterial methyltransferase enzyme M.SssI, which methylates unmodified
cytosines (C). The M.SssI treated DNA is then treated with bisulphite which converts 5fC
and 5caC to thymine (T) but does not convert cytosines (which have been converted
upstream to 5mC by M.SssI). Therefore, sequencing would indicate 5fC and 5caC as T,
whereas C/5mC/5hmC would be sequenced as C. Comparing bisulphite sequencing with
MAB-Seq results confirmed that TFF1 and GREB1 enhancers are composed almost
entirely of unmethylated cytosines and are not altered either in response to E2 treatment or
TDG depletion indicating that active demethylation at specific enhancers is not required
for E2 signaling (Figure 2-7D).
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Figure 2-7. Cytosines in TFF1 and GREB1 enhancers are epigenetically unmodified.
(A) Comparing TDG binding at sites regulated by E2 reveals that TDG binds to
hypomethylated locations. (B) Heatmap comparing methylation signal at sites of TDG
binding globally, reveals that TDG binds to hypomethylated sites. (C) MCF7 DNase signal
intensity, revealing that, globally, TDG binding occurs preferentially at sites which are
hypomethylated and ‘open’. (D) Bisulfite-sequencing and MAB-Seq at TFF1 after cells
were treated with scrambled siRNA (siControl) or siRNA targeting TDG (siTDG) and then
with or without E2 treatment. TFF1 enhancer is devoid of any methylation or activedemethylation metabolites and remains so in response to E2 or TDG depletion.
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2.2.6

TDG knockdown affects cell proliferation of MCF7 breast
cancer cells

Gene Ontology (GO) enrichment analysis was performed on genes which bind TDG and
are upregulated in response to E2. I found a significant enrichment at GO terms directly
related to proliferation, including “regulation of epithelial cell proliferation”, as well as
multiple terms implicating a role in “differentiation” and “Wnt signaling”. Wnt signaling
was a particularly interesting finding as TDG has recently been shown to directly
upregulate components of Wnt signaling pathway in colorectal cancer (CRC), and TDG
depletion inhibited proliferation of CRC cells both in vitro and in vivo (Xu et al., 2014).
To determine whether TDG plays a role in E2-dependent cell proliferation I deleted TDG
from MCF7 cells constitutively using CRISPR technology, or transiently using siRNA
(Figure 2-8).

In both systems, TDG depletion significantly decreases the E2-mediated

increase in proliferation compared to control cells, while also increasing sensitivity to the
anti-estrogen tamoxifen, with TDG depleted cells exhibiting a stronger cytostatic response
than controls (Figure 2-9A).
Estrogens and the anti-estrogens, such as tamoxifen, can modulate the proliferation
capacity of breast cancer cells in part by causing complex rearrangements of both the
cytoskeleton and adhesion apparatus (DePasquale et al., 1994; Ma et al., 2014; Millon et
al., 1989). Remarkably, I find that TDG depletion in MCF7 cells drastically alters decreases
their ability to adhere to the substratum, and to one another (Figure 2-9B and C). This
finding is important as anti-estrogens promote an invasive
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Figure 2-8. CRISPR-mediated deletion of TDG in MCF7 cells.
(A) To eliminate TDG protein from MCF7 cells I used the CRISPR/Cas-9 and pair guided
excision to remove a 490bp region of TDG which contained exon 2 and which also created
a frame-shift. (B) Protein levels of TDG in wildtype (WT) cells as well as those edited
using CRISPR or siRNA (C: control siRNA or non-targeting CRISPR, TDG: siRNA
targeting TDG or CRISPR targeting TDG).
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Figure 2-9. TDG depletion sensitizes MCF7 cells to Tamoxifen and produces
proliferation and attachment deficiencies.
(A) Growth curves examining responsiveness of CRISPR-mediated (upper panel) and
siRNA-mediated (lower panel) TDG knockout and knockdown respectively. MCF7 cells
were grown for 48-72h in charcoal-stripped phenol-red free media prior to treatment (left
panel) (n=3, p-value < 0.05, error bars show -/+ 1 standard deviation). (B) To examine
migration and adhesion MCF7 cells were treated with either scrambled siRNA or siRNA
targeting TDG and grown in regular media for 2 days prior to performing the cell-to-cell
adhesion assay. I found that MCF7s with depleted levels of TDG form significantly less
aggregates with one another (n = 4, error bars indicate standard deviation -/+ 1) (C)
Treatment of MCF7 cells with varying concentration of Trypsin revealed that those
depleted of TDG detached from tissue-plate substratum at lower concentrations (top panel)
and upon resuspension TDG depleted cells demonstrated re-attachment deficiencies,
remaining loosely attached and spherical while cells treated with siControl became
stabilized with visible ‘flattening’ indicative of cell-substratum contacts(bottom panel).
(D) To measure the effect of TDG on the migration and invasion capacity, TDG was
depleted in MCF7 cells using siRNA which were treated with or without Tamoxifen for
3d. Cells were harvested using 3mM EDTA and a suspension of 100,000 cells was
incubated at 37C for 72 in gelatin or Matrigel to test migration and invasion, respectively.
Cells were counted using ImageJ (n=4). MCF7s depleted of TDG show a drastically more
aggressive profile with cells migrating and invading gel at a significantly higher rate than
siControl cells.
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phenotype in breast cancer cells which have adhesion deficiencies (Borley et al., 2008).
Specifically, the researchers found that exposure to tamoxifen or fulvestrant promoted
invasion in cells maintaining poor cell-cell contacts. To test whether the adhesion defects
observed in TDG-depleted MCF7s promote migration or invasion, I depleted TDG in
MCF7s using siRNA and treated cells with the anti-estrogen tamoxifen and recorded their
ability to transverse gelatin, or Matrigel, respectively. While TDG depletion sensitizes
MCF7 cells to the cytostatic effects of tamoxifen, I find that MCF7 cells depleted of TDG
become much more aggressive, with significant increases in both migration and invasion
capacity (Figure 2-9D).

2.3

Discussion

Utilizing a combination of functional genomic analysis and biological assays, I have
identified a role for TDG in E2 dependent signaling in MCF7 breast cancer cells. In
response to E2 TDG localizes to distal regulatory sites of ERα target genes. Approximately
half of the TDG binding sites identified overlap with sites of E2-mediated ERα binding.
Importantly, in response to E2 TDG localizes to enhancer regions that play an important
role in the production of eRNAs and 3-dimensional re-organization important for target
gene transcription. By focusing on a subset of TDG target genes whose transcription is
upregulated in response to E2 treatment, I found that TDG depletion significantly reduces
the ability of E2 to induce transcription of eRNA produced at the enhancers, disrupts
looping, and inhibits transcription of the target genes.
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eRNA producing enhancers have several common characteristics that include increased
binding of transcriptional coactivators, greater chromatin accessibility and increased
formation of enhancer promoter looping. Although a direct functional role of eRNAs is
still unclear, mounting evidence supports the notion that eRNA production is not merely
transcriptional noise as previously suggested but play a functional role by contributing to
transcriptional activation of adjacent coding genes. While it remains unclear as to whether
eRNA transcription or the eRNA transcript per se are responsible for 3-dimensional reorganization that brings the enhancer and promoter into proximity of one another, I have
found that TDG depletion disrupts gene transcription broadly, interrupting both eRNA
production, 3-dimensional reorganization and activation of target gene transcription.
Furthermore, the finding that TDG binding occurs primarily outside of promoters suggests
that dynamics at enhancers play an important role in regulating ERα target gene expression.
Previous reports have suggested that stimulation of ERα signaling at some promoters
triggers a cyclical methylation/demethylation mechanism involving DNMTs (Métivier et
al., 2003, 2008). It was proposed that in addition to functioning as DNA
methyltransferases, DNMT3a/b are capable of deaminating 5mC when SAM is limiting.
The resulting G:T mispair is then excised by TDG and the base excision repair machinery
restores unmethylated cytosine. More recently reports have emerged showing that TDG
depletion in embryonic stem cells resulted in the accumulation of active demethylation
metabolites 5fC and 5caC at identified enhancer regions (Shen et al., 2013; Wu et al.,
2014). To determine whether active demethylation plays a role at enhancers I used MABSeq to establish a profile of the active demethylation intermediates 5fC/5caC at the site of
TDG binding pre- and post-E2 treatment and in conjunction with wildtype TDG levels or
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with siRNA-mediated depletion of TDG. I found that the TFF1 enhancer appears to be
composed entirely of unmodified cytosines regardless of E2 treatment. The observation
that TDG depletion in MCF7 breast cancer cells leads to no accumulation of 5fC/5caC
supports reports that the glycosylase activity of TDG is dispensable for E2 mediated
signaling and instead it is TDGs ability to act as a coactivator that potentiates ERα
activity(Chen et al., 2003).
The importance of E2-dependent signaling in breast cancer has been well documented. For
example, it has been demonstrated that growth, proliferation and metastatic nature of
MCF7 cells transplanted into nude mice are E2 dependent (Kubota et al., 1983). Treatment
of MCF7s with either E2, or the anti-estrogen tamoxifen, has been shown to cause changes
in proliferation and growth through complex large-scale rearrangements of the
cytoskeleton and adhesion apparatus (Borley et al., 2008; DePasquale et al., 1994;
Marchisio et al., 1986). Based on our findings that TDG seems to be intimately involved
with E2 signaling I investigated whether its role extends to proliferation. I found that
deleting TDG from MCF7 cells using either CRISPR technology or siRNA transfection
inhibited E2-dependent proliferation. Interestingly, GO analysis revealed that E2 causes
TDG binding and upregulation of genes involved in “Wnt signaling”, in addition to other
proliferation-related categories such as multiple GO terms referencing ‘differentiation’.
This is consistent with previous studies showing that TDG plays a critical role in the
progression of colorectal cancer by upregulating components of Wnt signaling pathway in
a CBP/p300 dependent manner. Importantly, researchers observed that TDG depletion
significantly inhibited proliferation of CRC cells in vitro and in vivo (Xu et al., 2014).
Taken together, our findings suggest that TDG’s role in Wnt signaling may perhaps extend
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outside of CRC and play an important role in breast cancer. Further studies will be required
to determine to what extent this may be the case.
We have found that TDG is also critical for maintaining proper cell-cell and cellsubstratum contacts in MCF7 cells and depletion of TDG leads to broad adhesion defects.
This is an important consideration as tamoxifen treatment has been shown to promote an
invasive phenotype in ER-positive breast cancers when cell-cell contacts are weak (Borley
et al., 2008). Migration and invasion assays have confirmed this, revealing that TDG
depletion results in a much more aggressive phenotype with cells demonstrating drastically
increased migration and invasion capacity in response to tamoxifen suggesting that TDG
possesses tumour suppressive properties despite being a positive regulator of estrogen
dependent cell growth. Based on these opposing roles I would predict that cells containing
a TDG mutation would not have a selective growth advantage and would be removed
before causing genetic and/or epigenetic changes resulting in cancer. This may explain why
homozygous mutations for TDG have not been identified in breast cancer based on TCGA
data set analysis. Taken together, our findings reveal TDG is important in E2 signaling by
regulating eRNA production at ER-targeted enhancers.

Furthermore, our functional

analysis revealed that TDG plays a critical role in proliferation in response to estrogens
and anti-estrogens. Further investigation into the potential for TDG as a therapeutic target
is strongly warranted.

2.4

Materials and methods

Cells culture, treatment and transfections
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MCF7 cells were obtained from ATCC and grown in low-glucose DMEM and 10% Fetal
Bovine Serum (FBS). Prior to treatment, cells were washed once with Phosphate Buffered
Saline (PBS) and grown in phenol red-free media containing charcoal stripped FBS (10%)
for 72h. Cells were then washed and treated with 100 nM E2 for specific time periods.
For siRNA mediated knockdowns, cells were incubated with Lipofectamine 2000
(LifeTechnologies) and siRNA targeting TDG (Dharmacon, M-040666-01) or scrambled
siRNA (Dharmacon, D-001210-03) for 24h, media was replaced with fresh media for 48h
at which point experiments were performed.
MCF7 CRISPR TDG-/CRISPR TDG-/- and CRISPR TDG+/+ MCF7 cells were generated as previously
described using wildtype Cas-9 and two cut sites:
Cut-site 1 (bottom strand): CACCGGTTATTAAGCACTCAGTAA,

Cut-site 1 (top

strand):

(top

strand):

(bottom

strand):

AACTTACTGAGTGCTTAATAACC;

(CACCGTCTGGGGAATAAAAGAACAT),

Cut-site

Cut-side

AAACATGTTCTTTTATTCCCCAGAC.
Primers used for detection:
Forward(GGCTGACTTGACAGGACTGA),
Reverse(CTGTGCTGAGCTGTAACGTG)(Hsu et al., 2014).
Protein extraction

2

2
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Whole cell protein extracts were obtained by harvesting cells in RIPA lysis buffer (50mM
Tris-pH 8.0, 150mM NaCl, 1% NP-40, 0.1% SDS, and protease inhibitor cocktail),
incubating on ice for 15min, followed by centrifugation for 15 min at 4°C (20,000 RCF).
Protein concentrations were normalized and proteins were separated using SDS-PAGE and
transferred to PVDF membrane. Blocking buffer containing PBS, 0.1% Tween-20 and 5%
skim milk powder was used for primary and secondary incubation as well as washes.
Protein of interest was visualized using Luminata Forte Western HRP Substrate (Cat. No.
WBLUF0100) and by exposure to autoradiography film (GE Healthcare).
RNA extraction, reverse transcription and qPCR
RNA extraction was performed using TRI-zol (Ambion) in accordance with the
manufacturer’s directions, with additional ethanol wash steps as needed. 2μg of total RNA
was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). mRNA levels were ascertained using pre-designed TaqMan probes (Applied
Biosystems) targeting the genes of interest, while enhancer RNA levels were monitored
using custom designed primers spanning the regions of interest and SYBR Green, per
manufacturer’s instructions. Experiments were performed with technical triplicates and
biological duplicates and run in a 96-well format using the StepOne Real-time PCR System
(Applied Biosystems) using GAPDH as a normalization control, unless otherwise noted.
Sequences of probes are listed in additional files (see Additional file 12).
ChIP-Seq preparation and analysis
MCF7 cells were serum starved for 3 days, treated with 100 nM E2 for 45min and then
ChIP was performed using a polyclonal TDG-targeting antibody that was antigen affinity
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chromatography purified (Thermo Fisher Cat. PA5-29140), as previously described, with
minor alterations (Thillainadesan et al., 2012). Briefly, cells were cross-linked using 1%
formaldehyde in PBS for 10 minutes under shaking at RT. 125 mM glycine in PBS was
added for 5min to quench the reaction. Cells were then washed twice with ice-cold PBS
and harvested in 1 ml of ice cold PBS buffer. The cells were then pelleted at 250g for 10
minutes, washed twice with ice-cold PBS (protease inhibitors added), and then lysed using
200 μl of lysis buffer (1% SDS, 50 mM Tris-HCl [pH 8.0], 10 mM EDTA, and protease
inhibitors) for 15 minutes on ice. The cell lysates were then sonicated, and cell lysate was
centrifuged at 15000 rpm for 15 minutes. An aliquot of the supernatant mixture was saved
as input DNA, and the remaining lysate was incubated with 5ug of antibody in 50 μl of
protein A/G dynabeads as per instructions. Immunoprecipitation was performed overnight
at 4°C under rotation. After the immunoprecipitation, the dynabeads were washed twice
using wash buffer I (0.1 % SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH
8.0], 150 mM NaCl), once with wash buffer II (0.1 % SDS, 1 % Triton X-100, 2 mM
EDTA, 20 mM Tris-HCl [pH 8.0], 500 mM NaCl), wash buffer III (0.25 M LiCl, 1% NP40, 1% Na-deoxycholate, 1 mM EDTA, 10 mM Tris-HCl [pH 8.0]) and twice with TrisEDTA buffer (pH 8.0). The chromatin was eluted using 150 μl of freshly made elution
buffer I (1% SDS, 0.1 M NaHCO3) twice at 65°C for 10 minutes. NaCl was added to the
eluates and input DNA to a final concentration of 0.3 M and both were incubated at 65°C
overnight. Immunoprecipitated DNA was purified using QIAquick PCR Purification Kit
(Qiagen) and was analyzed by quantitative PCR following ChIP in technical triplicates and
biological duplicates, unless otherwise noted. For high-throughput sequencing
immunoprecipitated DNA was sequenced in duplicates at The Centre for Applied
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Genomics Next Generation Sequencing facility (Toronto, Ontario). Sequenced reads were
mapped to the human genome (hg19) and Partek Genomic Suite was used to call peaks 100
bp bins at an FDR of 0.05. Peaks were further filtered, retaining only those peaks which
appeared in both replicates and which showed a greater-than 1.2-fold increase and had a pvalue < 0.05 in both replicates.
MAB-Seq
Methylase assisted bisulfite sequencing was performed according to Zhang Y et al. (2014).
Briefly, 1 μg of genomic DNA was treated with 4 U of M.SssI in a 20 μl reaction containing
160 mM of SAM. After 2h, the reaction was supplemented with an additional 4 U of M.SssI
and 160 mM SAM for an additional 4 hours. This was repeated three times. DNA was
purified by conventional phenol:chloroform:isoamyl-alcohol extraction followed by
ethanol precipitation after each round of treatment. DNA was then subject to bisulfite
conversion, sub-cloned using the TA cloning kit followed by sequencing.
Bisulfite sequencing
DNA was extracted from MCF7 cells using Sigma’s Genomic DNA extraction kit and 1
μg was used for bisulfite conversion using the EpiTect Bisulfite Kit (QIAGEN), according
to manufacturer’s instructions.
Bioinformatics
All datasets used in this study were either based on the hg19 genome or were converted to
the hg19 genome using the tool liftOver (http://genome.ucsc.edu/cgi-bin/hgLiftOver).
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Mapping peaks to annotated genome was done using Cis-regulatory Element Annotation
System (CEAS-Package-1.0.2, http://liulab.dfci.harvard.edu/CEAS/). To mark distance
from known transcription sites, Region-gene association graphs were generated using the
Genomic Regions Enrichment of Annotations Tool (version 3.0.0) and the following
parameters: Association rule: Basal+extension: 5000 bp upstream, 1000 bp downstream,
1x106 bp max extension and curated regulatory domains included.
To determine the relative measure of similarity between E2-dependant TDG localization
and that of other transcription factors I downloaded all 690 datasets from the Transcription
Factor

ChIP-Seq

Uniform

Peaks

from

ENCODE/Analysis

at

UCSC

(https://genome.ucsc.edu/ENCODE/downloads.html) and determined the Fisher exact test
and the pairwise Jaccard statistic using the Bedtools (2.25.0) options “fisher” and
“jaccard”, with default parameters, respectively.
All motif analysis was performed using the latest version of Homer software (version 3.12)
(http://homer.ucsd.edu/homer/).

Peak visualization was performed using IGV

(version/site) with group normalization applied where applicable.
Contrasting TDG localization with gene upregulation was done using GREAT software
(using default conditions) to generate a list of genes with which TDG associates and crosscorrelating this list with expression data.
GRO-Seq data set was overlapped with sites of TDG binding or control sites (sites which
contained the same sized peaks but distributed randomly using the Bedtools (2.25.0)
“shuffle” option) using Homer software (v. 3.12) following software guidelines and default
parameters. To generate heatmaps of looping at sites of TDG binding publicly available
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ChIA-PET data was overlapped with sites of TDG binding or control sites (sites which
contained the same sized peaks but distributed randomly using Bedtools (2.25.0) shuffle)
using deepTools2 (Ramírez et al., 2016).
Gene

Ontology

analysis

was

completed

using

ConsensusPathDB

(http://cpdb.molgen.mpg.de/) using default settings. Cut-off was set at q-value > 0.05.
Chromosome Conformation Capture (3C)
MCF7 cells were treated with 100 nM E2 for 45 min and were cross-linked using 1%
formaldehyde for 10 min. The cells were then exposed to Trypsin for 5 min at 37°C
followed by 5 min incubation with the 3C lysis buffer at 4°C. 3C was then performed as
previously described (Hagege et al., 2007).
Cell-to-cell adhesion
The cell-cell adhesion assay was done as previously described (Rodriguez et al., 2008).
Briefly, plates were rinsed twice with PBS and cells were dissociated with 3 mM EDTA.
Cells were collected and spun at 400 RCF for 5 minutes, then resuspended in DMEM media
and passed through a cell strainer to dissociate cell clusters. Approximately 200,000 cells
were added in the appropriate media (DMEM) onto a 6cm petri dish. Plates were incubated
at 37ºC on a shaking platform for 30 minutes. After this incubation period, 10 different
fields of view were taken per dish at 10x objective. Clusters of > 4 cells were then counted
and counts from 10 fields of view were added together for each plate.
For cell-substrate adhesion assays MCF7 cells were grown to confluency and then treated
with varying concentrations of Trypsin for 2 minutes, at which point images were obtained.
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For re-adhesion assays cells were trypsinized and resuspended in full media (DMEM +
10% FBS) and re-plated onto 6 well. Images were obtained at the times documented.
Migration and Invasion
For migration assays, transwell inserts with 8.0 um pores (Corning, Cat. No. 3422) were
coated with 3 µg of gelatin and allowed to dry overnight at room temperature in a sterile
environment. The following morning, the gelatin-coated filters were reconstituted with
100uL serum-free DMEM for 90 minutes on a shaker. For invasion assays, transwell inserts
with 8.0 um pores were coated with 100 µL of 1mg/mL Matrigel (Corning, Cat. No.
356234) and incubated at 37ºC for one hour to allow for solidification of the Matrigel layer.
For both assays, MCF7 cells transiently transfected with siC or siTDG RNA for 3 days
prior to being treated with or without tamoxifen. 3 days after treatment, cells were
harvested using 3mM EDTA. A cell suspension of 100,000 cells in DMEM + 0.1% BSA
was added to the upper well of each transwell insert, and 750uL of DMEM + 10% FBS
was added to the lower chamber as a chemoattractant. The cells were incubated at 37ºC
and allowed to migrate or invade for 72 h. After this incubation period, the transwell
membranes were fixed with 1% glutaraldehyde for 20 min, followed by a 15-min stain with
full strength hematoxylin, and brief dip in 1% ammonium hydroxide. Non-migrating and
non-invading cells were wiped off the upper surface of the membrane with a cotton swab.
Images of 3 non-overlapping fields of view per well were acquired using Image-Pro
Analysis Software on an inverted microscope at 10X objective. Cells were counted using
ImageJ. Means derived from four replicates were used during analysis.
Primers used in study listed in Table 2-1.

103

File Sources listed in Table 2-2.
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Table 2-1. Primers used in study.
ChIP Primers
TFF1_eChIP_F

GTTTGTGACCCAGGCATCTT

TFF1_eChIP_R

CAGGGTCCTGTCATTGTGTG

GREB1_ChIP_F

GCTAACCATGCTGCAAATGA

GREB1_ChIP_R

ACACAGTCAGGGCAAAGGAC

SIAH2e_F

ATCCAATTGCTGCAGGTCAC

SIAH2e_R

TCCAGGCAAGGTCACTAAGG

TSKUe_F

TCAGAACGCTCGACCTAGTC

TSKUe_R

TCAGGGCAGGACACATGATT

Neg. Control_F

CATGATTCTCGGGATTTTTCTC

Neg. Control_R

GACAGCTCTGCACCTGTCAT

3C Primers
GREB1_3C_Bait

GGGTGCTTAGCATGGTACCTGGCAC

GREB1_3C_Enhancer

GATCATACAGTCCCGTCTTCCCTTCCTTCA

Enhancer RNA Primers
TFF1e_F1

GTTTGTGACCCAGGCATCTT

TFF1e_R1

CAGGGTCCTGTCATTGTGTG

TFF1e_F2

AGGGGATGTGTGTGAGAAGG

TFF1e_R2

GCTTCGAGACAGTGGGAGTC

GREN1eRNA_F1

GCTAACCATGCTGCAAATGA

GREB1eRNA-R1

ACACAGTCAGGGCAAAGGAC

GREB1eRNA_F2

TTGATCTGCTCTTGCCTGAA

GREB1eRNA-R2

GTCCTTTGCCCTGACTGTGT

SIAH2e_F

ATCCAATTGCTGCAGGTCAC
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SIAH2e_R

TCCAGGCAAGGTCACTAAGG

TSKUe_F

TCAGAACGCTCGACCTAGTC

TSKUe_R

TCAGGGCAGGACACATGATT

Bisulfite sequencing Primers
TFF1_enhancer_bis_REV

GAATTGGAGGGGAGTAGTATGAG

TFF1_enhancer_bis_FOR

GACACACCAAAAAACATCCC

GREB1_enchancer_bis_FOR

GGTTTTAAGAGGATTATAAAGAGTG

GREB1_enchancer_bis_REV

CCCACACTTCCAAAATAACAC

Taq-man probes

Catalogue Number

GAPDH

Hs02758991_g1

GREB1

Hs00536409_m1

TFF1

Hs00170216_m1

HSPB8

Hs00205056_m1

SIAH2

Hs00192581_m1

TSKU

Hs00539298_s1
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Table 2-2. External file sources used in study.
Assay

Target

Treatment

ENCODE

GEO

MCF7
gene
expression

N/A

-/+E2

N/A

GSE36683

MCF-7 Global
Bisulfite
sequencing

N/A

N/A

N/A

GSE54693

Gro-seq

N/A

-/+E2

N/A

GSE45822

ChIA-PET

POLR2A

N/A

ENCSR000CAA

N/A

ChIA-PET

CTCF

N/A

ENCSR000CAD

N/A

ChIA-PET

ESR1

N/A

ENCSR000BZZ

N/A

ChIA-PET

POLR2A

N/A

ENCSR000CAA

N/A

ChIP-seq

H3K4me2

N/A

ENCSR875KOJ

N/A

ChIP-seq

H3K4me3

N/A

ENCSR000DWJ

N/A

ChIP-seq

H3K9me3

N/A

ENCSR000EWQ

N/A

ChIP-seq

H3K27me3

N/A

ENCSR000EWP

N/A

ChIP-seq

H3K27Ac

N/A

ENCSR000EWR

N/A

ChIP-seq

GATA3

N/A

ENCSR000EWV

N/A

ChIP-seq

TCF7L2

N/A

ENCSR000EWT

N/A

ChIP-seq

ZNF217

N/A

ENCSR000EWU

N/A

ChIP-seq

EP300

N/A

ENCSR000BTR

GSM1010800

ChIP-seq

HA_E2F1

N/A

ENCSR000EWX

GSM935477

ChIA-PET

ESR1

N/A

ENCSR000BZZ

GSM970212

DNAse-Seq

N/A

N/A

ENCSR000EPJ

GSM736588
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3.1

Introduction

Senescence describes a state of persistent cell-cycle arrest that was originally observed in
mammalian cells after excessive passaging (Hayflick and Moorhead, 1961). The cause of
senescence was originally attributed to excessive telomere depletion that occurs as a
consequence of the ‘end replication problem’. Once cells have reached their proliferative
potential, telomere depletion results in a complex DNA damage response that ultimately
leads to the upregulation of several cell-cycle inhibitors and depletion of pro-mitotic
signals, resulting in observed cell-cycle arrest (d’Adda di Fagagna et al., 2003). In addition
to prolonged passaging, a wide range of stressors such as hydrogen peroxide treatment
(Guo et al., 2010), oncogene activation (Benanti and Galloway, 2004), and exposure to
U.V. radiation (Mirzayans et al., 2008) induce senescence in a telomere independent
manner. Furthermore, senescence has been observed to play critical roles in many
fundamental processes including tissue remodeling, wound healing, aging, and most
recently, embryonic development (Muñoz-Espín et al., 2013; Storer et al., 2013; Zhang et
al., 2014). Senescent cells differ from their normal counterparts in numerous ways
including having an enlarged cytoplasm, being able

to cleave X-gal under acidic

conditions, and expressing a unique protein profile that includes various tumor suppressors
(i.e. p53, p21,ARF) including CKDN2A (Salama et al., 2014). Most cells with an activated
senescence program, while non-proliferative, remain metabolically active and exhibit a
“Senescence Associated Secretory Phenotype” (SASP), secreting cytokines, chemokines,
metalloproteases and growth factors (Pérez-Mancera et al., 2014; Storer et al., 2013). This
secretion profile results in inflammation and recruitment of immune cells which then act
to clear the senescent and/or damaged cells. Senescence of cells followed by immune
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system engagement and clearance is believed to underpin the beneficial effects of
senescence in tumor suppression, tissue remodeling and embryonic development. In
contrast, the accumulation of senesced cells, or the inability to clear them, has been
implicated in the progression of disease, increased tumor aggressiveness, accelerated
aging, and other pathologies (Lujambio, 2016).
Although cells undergoing senescence share certain common markers, it has become
increasingly clear that the molecular mechanisms that regulate and establish senescence
can vary depending on cell-type or context (i.e. what stressor led to the senescence). While
therapeutic approaches, both pro- and anti-senescence have been considered, a deeper
understanding of the processes that underlie senescence is required to determine under
what contexts their use is warranted or appropriate.
A chromosomal region highly implicated in early senescence is the INK4 locus which
encodes the cell cycle inhibitors CDKN2A, CDKN2B, and p14ARF. p14ARF inhibits
mdm2 which is a negative transcriptional regulator of p53. This causes an increase in the
concentration of p53 and induces cell-cycle arrest through the p53 pathway (Williams et
al., 2014). CDKN2B and CDKN2A both act by inhibiting CDK4/6, which in turn prevents
phosphorylation of Rb, allowing it to remain bound to E2F1, thereby preventing activation
of genes required for G1/S transition (Williams et al., 2014). Importantly, CDKN2A has
been shown to be critical in the maintenance of senescence and preventing cells from reentering the cell-cycle (Rayess et al., 2012). The importance of this locus continues to be
highlighted by numerous studies showing that the absence of these tumor suppressors,
often due to epigenetic silencing or deletion, is tightly correlated with the onset and
progression of various cancers corresponding with the loss of senescence and, often times,
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poor prognosis (Beauséjour et al., 2003; Bihl et al., 2012; Lou-Qian et al., 2013; Shim et
al., 2000; Wang et al., 2012) . Furthermore, epigenetic silencing of CDKN2A involving
promoter methylation, has been implicated as a mechanism through which cancer cells can
overcome the senescence program (Monasor et al., 2013). In certain contexts,
demethylation of the CDKN2A promoter has been shown to lead to its re-expression
resulting in cellular senescence (Vogt et al., 1998). Understanding how transcription of
these products is regulated is critical to developing our understanding of how cancer
overcomes inherent barriers to proliferation and will help us to identify potential
therapeutic targets.
Thymine-DNA Glycosylase (TDG), a member of the monofunctional glycosylase family,
plays an important role in activating the INK4 protein CDKN2B (Thillainadesan et al.,
2012). TDG is a base excision repair enzyme capable of catalyzing the removal of certain
mispaired nucleotides (Cortázar et al., 2007). Upon cleaving its substrate, TDG leaves an
abasic site that is subsequently repaired by the BER program(Sjolund et al., 2013).
Interestingly, TDG associates with other coregulators, such as the Creb binding protein and
p300 (CBP/p300)(Tini et al., 2002) as well as steroid receptor coactivators (SRCs)(Hu et
al., 2010) and can function as a coactivator by interacting with various transcription factors,
such as nuclear hormone receptors (Chen et al., 2003; Um et al., 1998).
The generation of TDG homozygous knockout mice revealed that the loss of TDG results
in embryonic lethality at day E11.5 (Cortázar et al., 2011; Cortellino et al., 2011).
Importantly, aberrant promoter hypermethylation, concomitant with the emergence of
repressive histone marks and loss of activating marks at many genes was observed.
Furthermore, the targeting of coregulators and other proteins known to interact with TDG,
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such as CBP/p300 was also disrupted. Surprisingly, increases in random DNA mutation
due to loss of TDG was not observed (Wu and Zhang, 2014) suggesting that the loss of
epigenetic reprogramming during development is likely responsible for the lethality.
Complementary studies examining the effects of TDG loss in mouse embryonic stem cells
(mESCs) showed an accumulation of TDG substrates (5fC and 5caC) known to be
generated through the proposed active demethylation pathway, confirming that loss of
TDG impacts active demethylation in development (Raiber et al., 2012; Shen et al., 2013;
Song et al., 2013).
Recent studies have shown that mouse embryo’s initiate a robust senescence program
during development that is maintained from E10.5 to E18.5. During this time, distinct
patterns of strongly senescing cell can be observed at various structures including the otic
vesicle, fusing neural tube and lining of the limbs. Importantly, mice deficient in genes
critical to the initiation and/or maintenance of senescence exhibit defects in senescence
patterning and developmental abnormalities at these structures (Muñoz-Espín et al., 2013;
Storer et al., 2013; Zhang et al., 2014).
In this study, I explored the role that TDG plays in senescence in two distinct systems: fully
differentiated lung fibroblasts as well as in embryonic development. I find that exposing
the human lung fibroblast cell-line, IMR-90, to oxidative stress in the form of sublethal
doses of H2O2, initiates senescence as was evident through cell-cycle arrest, CDKN2A
production, and positive β-galactosidase staining. siRNA-mediated Depletion of TDG
using siRNA diminishes the H2O2-mediated cell-cycle arrest and positive β-galactosidase
staining. Importantly, I show that TDG depletion prevents CDKN2A upregulation in
response to H2O2 and cells depleted of TDG have lower levels of CDKN2A than their wild-
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type counterparts. Mechanistically, I show that TDG can bind to the CDKN2A promoter
and this binding is significantly increased when cells are expose to H2O2. Importantly, I
find that TDG is required for the recruitment of CBP/p300, a histone acetyltransferase that
plays critical roles in transcriptional upregulation.
To explore whether TDG played any role in developmental senescence I generated a TDGknockout mouse model and stained embryos for β-galactosidase. Remarkably, I find that
TDG-KO and TDG-HET mice exhibit perturbed senescence patterning at specific
structures during development. RNA-Seq on whole mount embryos revealed that
transcription differences between TDG-KO and WT mice are not global and instead occur
at a specific set of genes. However, I show that TDG’s role in developmental senescence
occurs independent of its role in regulating CDKN2A and using gene-enrichment analysis
find that TDG deletion causes a downregulation of genes which are important to
establishing senescence and specifically SASP. Taken together our findings suggest that
TDG is a key regulator of senescence and may impact senescence in other contexts.

3.2
3.2.1

Results
TDG is required for developmental and H2O2-induced
senescence.

Sublethal doses of H2O2 have been previously show to induce senescence in IMR90 human
lung fibroblast cells, causing them to cease proliferation and stall in the G1 phase of the
cell cycle, with cells exhibit the typical markers of senescence (Chen et al., 1998a). To
establish whether TDG plays a functional role in initiation or maintenance of the
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senescence program in fibroblasts I first depleted TDG from IMR-90 cells using siRNA
targeting TDG and then treated cells with senescence-inducing concentrations of H2O2 and
monitored their proliferation. In response to H2O2 IMR90s show substantial reduction in
proliferation capacity and depletion of TDG increased proliferation compared to controls
(Figure 3-1A). In addition to reduced proliferation, a widely used marker for senescence
is β-galactosidase activity at an acidic pH. In wild-type cells, β-galactosidase is not active
at a pH of 6.0, however cells with an active senescence program exhibit a drastically
increased lysosomal mass and increased levels of lysosomal β-galactosidase allowing it to
cleave its substrate under acidic conditions (Dimri et al., 1995; Kurz et al., 2000). To test
whether the decrease in proliferation response upon TDG depletion is indeed due to a
defective senescence program I again exposed IMR90s to sublethal levels of H2O2 post
TDG depletion and measured the ability to cleave 5-bromo-4-chloro-3-indolyl-β-Dgalactopyranoside (X-gal), a β-galactosidase substrate (Dimri et al., 1995). While the
population of IMR90s already contains a small subpopulation of senescent cells prior to
treatment, H2O2 causes the number of senescent cells increases approximately 5-fold.
Importantly, consistent with the proliferation assay results, TDG depleted IMR90s show
significantly less staining than the controls (Figure 3-1B). I repeated this experiment in
another fibroblast cell line (HFL-1 cells) and found a similar dependency on TDG to
initiate senescence program, suggesting that the results in IMR90s may extend to other
adult tissue as well (Figure 3-1C).
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Figure 3-1. TDG is required for proper senescence response in fibroblasts.
(A) IMR90’s were treated with either control or H2O2, and either siRNA targeting TDG
or a scrambled non-targeting siRNA. Left panel – Western Blot. Right panel – Growth
curve (Cells were counted every 24 h (n=3)) (B) Left panel - IMR90 cells were treated with
siRNA for 3 d then treated with H2O2 for 5 d at which point they were stained for the
senescence marker β-galactosidase using X-gal. Right panel - Manual quantification of
staining for IMR-90s. (C) Staining of HFL-1 cells.
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Recent work has revealed that senescence plays an important role in developing mouse
embryos(Ewald et al., 2010; Muñoz-Espín et al., 2013; Storer et al., 2013; Zhang et al.,
2014). TDG knockout mouse models have previously shown that homozygous deletion of
TDG is embryonic lethal, however the role of senescence in these models was not
established. To determine whether TDG is important for the establishment of correct
developmental senescence patterning, our lab developed mice containing a homozygous
and heterozygous deletion of TDG-KO and TDG-HET, respectively (Figure 3-2 A-C).
Mice heterozygous for TDG were bred and at E10.5 pups were sacrificed and stained for
β-galactosidase activity. Using a double-blind study, I found that wild-type mice display
senescence patterning consistent with previous reports showing specific staining of various
structures including the ridges of front and hind limbs as well as the otic vesicles.
Remarkably, mice depleted of TDG show severe disruptions in a dose dependent manner,
with homozygous TDG-KO mice showing more severe disruption, based on staining, than
the TDG-HET mice (Figure 3-2D and 2E).

3.2.2

TDG mediates senescence in IMR90s by regulating
CDKN2A transcription.

In addition to G1-phase arrest and β-galactosidase staining at pH 6.0, CDKN2A is an
established marker that is upregulated in senescent cells (Figure 3-3A). To establish
whether TDG regulates transcription of CDKN2A, I treated IMR90 cells with a sub-lethal
concentration of H2O2, following siRNA mediated TDG depletion, and immunoblotted for
CDKN2A. I observed that CDKN2A expression is increased in
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Figure 3-2. TDG is required for senescence response during development.
(A) Schematic diagram of the strategy used to create the TDG-knockout mouse using the
flox-CRE system (B) Western blot of whole cell lysate of tissue obtained from TDG-WT
and TDG-KO embryos. (C) RNA-Seq analysis of the TDG locus in mice. The TDG
transcript was disrupted by removing exon 2. (D) β-Galactosidase staining of mouse
embryos revealed a defect in senescence in TDG-KO and HET mice in the chest cavity
(red perimeter), at the otic vesicle (white arrows) and apical ectodermal ridge. (H) Staining
at the otic vesicles, as well as both front and back limb buds on both sides of the body was
recorded and shown as a percentage of total (n = 10, N/A = indeterminate due to absence
of structure or inconclusive staining).
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response to H2O2, and depletion of TDG prevents the H2O2-mediated increase (Figure 33B and 3C). IMR90s are typically believed to be a “late passage” cell line and possess
“high” basal levels of CDKN2A, consistent with our observations (Benanti and Galloway,
2004). Surprisingly however, TDG depletion not only prevented the H2O2-mediated
increase in CDKN2A protein levels but cells treated with siTDG exhibited lower levels
than our wild-type controls. To explore this further, I titrated the amount of siTDG
transfected and observed that CDKN2A levels progressively decrease in response to
increased TDG depletion (Figure 3-3D), confirming that CDKN2A expression is
dependent on endogenous TDG levels in IMR90s

3.2.3

TDG functions as a Transcriptional Coactivator in IMR90
cells

TDG plays a broad range of roles as a co-activator and mediates the excision of TET
catalyzed 5mC metabolites during active demethylation. As a co-activator, TDG has been
shown to interact and co-localize with various nuclear receptors and potentiate their
transcriptional activity by recruiting additional co-factors (Hassan et al., 2017; Sjolund et
al., 2013). Importantly, TDG has been previously shown, in reporter assays, to regulate
transcription through the active demethylation of the CDKN2A locus, presumably by
directly acting on the locus (Hu et al., 2010). To test whether a similar mechanism governs
H2O2 dependent transcription of CDKN2A in IMR90 cells, I first performed a ChIP using
a TDG-specific antibody followed by qPCR using primers targeting a CpG that overlaps
the CDKN2A promoter after treating cells with control or H2O2. H2O2 treatment causes
TDG localization to the CpG island overlapping the

140

Figure 3-3. TDG regulates CKDN2A expression.
(A) CDKN2A disrupts progression through the cell cycle by inhibiting CDK4/6. This
prevents phosphorylation of RB. Rb in turn inhibits E2F from transcriptionally activating
genes critical for the cell to progress into S phase. (B) Western blot of CDKN2A. CDKN2A
response to varying levels of H2O2 was assessed in IMR90s by treating cells with H2O2 (C)
Top panel – Western blot measuring effects of TDG depletion on H2O2 mediated CDKN2A
induction. IMR90 cells were treated with siRNA targeting TDG or a control for 3 d
followed by treatment with H2O2 or control for 5 d. Bottom panel – densitometry of
western blot. (D) Top panel - Western blot showing effect of increased concentration of
siRNA targeting TDG on endogenous CDKN2a levels in IMR90s. Bottom panel Quantitation of western blot using densitometry.
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CDKN2A promoter (Figure 3-4A-C). To determine whether TDG localization impacts the
methylation status of the CDKN2A promoter, I performed bisulfite sequencing on a region
of the same CpG island to which TDG localizes. Consistent with the high basal levels of
CDKN2A observed in IMR90 cells, bisulfite sequencing revealed that CpGs in the region
are hypomethylated and treatment with H2O2 or TDG depletion did not significantly
change the methylation status (Figure 3-4D).

These findings suggested that TDG

regulation of CDKN2A levels in response to H2O2 is independent of its role in active
demethylation.
CBP and p300 are coactivators and lysine acetyltransferases that share a large sequence
homology with one another and therefore contain the same set of functional domains and
interacting partners. While recent reports have observed differences in the specificity when
certain factors (i.e. histones or acetyl-coA) are limited, functionally CBP and p300 are
considered to be largely interchangeable, and are often referred to collectively as CBP/p300
(Kasper et al., 2010; Roth et al., 2001).
TDG interacts directly with CBP/p300 and has been shown to colocalize with p300 at many
regulatory regions in ES cells (Hassan et al., 2017; Thillainadesan et al., 2012; Tini et al.,
2002; Xu et al., 2014). To explore the possibility that TDG dependent induction of
CDKN2A involves recruitment of CBP/p300, I treated IMR90 cells with H2O2 and
performed ChIP-qPCR using a CBP-specific antibody. CBP is indeed recruited to the
CDKN2A promoter in response to H2O2 and remarkably, TDG depletion using siRNA
prevents this recruitment (Figure 3-4E and F). Interestingly, inspection of the CpG island
overlapping the CDKN2A promoter revealed a TCF4 binding motif near the site I
interrogated for TDG/CBP binding. While it remains to be seen whether TCF4 mediates
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Figure 3-4. TDG’s role limited to that of scaffold.
(A) Structure of CDKN2A locus with the primers used indicated. (B) Western Blot
showing that while siRNA mediated TDG depletion depletes TDG levels, H2O2 does not
appear to affect TDG protein levels. (C) To assess whether or not TDG was localized to
the CDKN2A promoter I performed a ChIP using TDG-specific antibody and found
significant accumulation of TDG in response to H2O2 treatment (*, p<0.05). (D) Bisulfite
sequencing of CDKN2A promoter reveals a relatively unmethylated landscape. (E and F)
ChIP and ChIP-qPCR for CBP at CDKN2A. IMR90 cells were treated with siRNA
targeting TDG or control for 3 d. Cells were treated with H2O2 for 2 h and then allowed to
recover for 5 days before ChIP was performed (qPCR, n=3, standard error shown, p-value
< 0.05).
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TDG recruitment in the context of senescence, TDG is able to directly interact with TCF4
and has been shown to be required for TCF4 mediated induction in other systems, such as
Wnt signaling in colorectal cancer (Xu et al., 2014). Importantly, TDG interacts with CBP
in this context, and target gene induction was concomitant with H3 acetylation of nearby
histones (presumably due to CBP recruitment); effects which were lost when TDG was
depleted (Xu et al., 2014). TCF4 and CBP have also been implicated in activating
CDKN2A transcription, however whether this was through direct binding of the CDKN2A
promoter by TCF4 is unclear (Saegusa et al., 2006). Finally, my own work on TDG’s role
in ER-signaling found that one of the most common binding sites overlapping that of E2dependent TDG binding in MCF7s, is also TCF4 – suggesting that the relationship between
TDG and TCF-4 may span different biological contexts, perhaps even the induction of
senescence. Collectively, our findings point to TDG regulating CDKN2A transcription
through its actions as a co-activator, possibly through its recruitment by TCF4, in an activedemethylation independent manner.

3.2.4

TDGs role in developmental senescence is independent of
CDKN2A induction.

To explore the mechanism governing TDG’s role in developmental senescence I performed
an RNA-Seq on mouse embryos from TDG-WT and TDG-KO cohorts. Bioinformatic
analysis revealed that statistically significant differences in expression are limited to a
small set of genes (Table 3-1 and Figure 3-5A). Consistent with the role of TDG as a coactivator, I find that 89% of the genes which are differentially expressed are downregulated
in TDG knockdown mice as compared to the WT mice (Figure 3-5B and C). In contrast to

146

our experiments in adult fibroblasts, I find that CDKN2A is not transcribed in developing
embryos and therefore no changes in CDKN2A levels were detected between our cohorts
(Figure 3-5D). These findings suggest that TDG’s role in initiating or maintaining
senescence is broader than I originally anticipated, possibly controlling senescence during
development through different/altered pathways than in adult tissue. SenescenceAssociated Secretory Phenotype (SASP) plays a critical role in recruitment of immune cells
in order to clear senesced cells and is believed to be critical in wound healing, tumor
elimination, or tissue remodeling (Lujambio, 2016). More recently the pathway has been
shown to be active during development in cells of structures undergoing senescence,
suggesting that the clearing of senescent cells is an important aspect of tissue remodeling
during development (Storer et al., 2013). To determine if TDG plays a role in SASP during
development, I performed gene-list enrichment analysis on the set of genes which are
differentially expressed between TDG-WT and TDG-KO. I find that the top hits include,
“Cellular response to stress”, “Oxidative Stress Induced Senescence” and “SenescenceAssociated Secretory Phenotype (SASP)” (Figure 3-5E). Pathway analysis showed
enrichment for WNT and HEDGEHOG pathways, both of which are dysregulated during
developmental senescence (Muñoz-Espín et al., 2013).
To obtain a better sense of potential mechanisms governing the transcription of our gene
list, I used the ENCODE database, which contains ChIP information detailing transcription
factor and coactivator binding for various transcription factors under different conditions,
to explore whether genes in our list are known to be targeted by any other factors.
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Table 3-1. Gene list of differentially expressed genes comparing WT to TDG-KO
mice.
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Gene Name

Fold Change (KO/WT)

Hist1h3b

-4.604730112

Rn45s

-4.28755873

Hist1h2af

-3.684236058

Hist1h2ak

-3.67188656

Hist2h2ac

-3.615758371

Hist1h4d

-2.972867629

Hist1h3c

-2.860687465

Hist1h4a

-2.823992808

Hist1h4f

-2.628734762

Hist1h2bc

-2.584279348

Hist1h3e

-2.565768432

Hist1h4h

-2.561694357

Hist1h2bn

-2.547296724

Josd2

-2.389889399

Hist1h4b

-2.358090726

Hist1h4c

-2.355917092

Ttr

-2.351071426

Hist1h3i

-2.305073585

Hist1h3d

-2.252757216

Hist1h2bg

-2.241319199

Hist2h4

-2.235437136

Hist4h4

-2.209367652

Hist1h4m

-2.198653402

Hist1h3g

-2.192280045

Rpph1

-2.178734496

Hist1h3a

-2.163438152

Hist1h3f

-2.136669521

Rpl36

-2.034155925
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Wnt8b

-2.021315877

C2cd2l

-1.986464597

Nckap5l

-1.788602022

Ccdc124

-1.776946992

Hist1h2bh

-1.776436736

Hist1h1c

-1.695497477

Hist3h2a

-1.66625845

Crocc

-1.638163022

Emilin1

-1.631945943

Ahdc1

-1.622061063

Tmem132a

-1.591152977

Atp13a2

-1.581161763

Ppp1r12c

-1.573188929

Csnk1g2

-1.545582514

Hist1h2bm

-1.538673476

Scaf1

-1.536761083

Rmrp

-1.518211721

Megf6

-1.511055323

Hist1h1d

-1.510416071

Pold1

-1.505032589

Rplp2

-1.489131856

Pcnxl3

-1.483877776

Ints1

-1.478801309

Rps26

-1.476415794

Ckb

-1.47591883

Col2a1

-1.452279539

Gnb2

-1.443453794

Myh7

1.660958515

Actc1

1.826025366

Ttn

1.8467956
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Myom1

1.953907359

Myl1

2.075705638

Nppa

3.236279189

Myl2

3.328548459
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Figure 3-5. Transcription profiles of TDG deficient mice compared to WT.
(A) PCA analysis comparing WT and KO mice found that the global transcription profiles
were similar between cohorts and, instead, what I found was that TDG deletion caused a
significant change in a small subset of genes. (B) Changes in gene-expression between
TDG-KO and TDG-WT mice revealed that most genes underwent down regulation in
TDG-KO mice as compared to TDG-WT, consistent with previous reports finding that
TDG acts primarily as a co-activator, c. (C) Heatmap looking at gene-expression profiles
in WT and KO mice. (D) Transcript levels of CDKN2A and various house-keeping genes
in both TDG-KO and WT mice. (E) To determine what pathways were affected by TDG
knockdown gene enrichment analysis was performed using the Reactome database (Subset
of significant results shown).
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Remarkably, I find that the highest enrichment came from p300 and SP1: ChIP analysis
revealed that 32 (48%) of the genes in our list have been shown to recruit p300, while 39
(59%) have shown to recruit SP1 (Table 3-2). This data suggests that the mechanism
governing expression of these genes may be similar to the mechanism governing H2O2mediated expression of CDKN2A in IMR90, however further work is required to test this
proposition.

Collectively these suggest that TDG is required for developmental

senescence, and that its role is independent of CDKN2A regulation.

3.3

Discussion

Senescence, originally shown to be a cellular program that limits proliferative potential,
has more recently been shown to be a critical component of various fundamental processes,
modulating cellular response to oncogenic stress and reactive oxygen species, wound
healing, tissue remodeling and, most recently, embryonic development. While a proper
senescence program is able to promote positive outcomes, errors in senescence have been
shown to be detrimental to health. Building a comprehensive understanding of how
senescence is initiated and maintained is a critical step toward developing therapies that
can appropriately modulate senescence in a therapeutic context.
In this study I find that TDG, a base-excision protein with an expanding list of roles, is a
critical mediator of distinct forms of senescence. In a model of senescence in the IMR90
human lung fibroblast cell, I demonstrated that depletion of TDG leads to an attenuated
response to H2O2: effects of H2O2 on proliferation and β-galactosidase staining are
attenuated and CDKN2A induction abrogated. Furthermore, in response to H2O2, I show
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Table 3-2. ENCODE transcription factor binding at genes whose transcription was
significantly altered in WT vs TDG-KO mice.
The list of gene that were identified as being significantly downregulated upon TDG
knockout in our RNA-Seq data were compared to the ENCODE (2014) database using
Enrichr software. Bolded are instances of SP1 and p300.
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Term

Adjusted P-value

Genes

0.000187686

HIST1H2BN;CCDC124;HIST2H2AC;HIST1H3A;NPPA;RPL36;RPLP2;EMILIN1;HIST1H3I;CKB;
HIST1H3B;HIST1H3E;INTS1;HIST1H2AK;NCKAP5L;TMEM132A;JOSD2;SCAF1;RPS26;HIST1
H4A;HIST1H4B;HIST4H4;GNB2;HIST1H4H;HIST1H2BH;HIST1H2BG;HIST1H4C;HIST1H4D;
PPP1R12C;AHDC1;HIST1H4F;HIST1H2BC

SP1_H1

0.000187686

HIST1H2BN;HIST1H2BM;CCDC124;HIST2H2AC;RPPH1;HIST1H3A;POLD1;HIST1H3F;RPL3
6;HIST1H3G;RPLP2;HIST1H3I;HIST1H3B;HIST1H3D;RMRP;HIST1H3E;NCKAP5L;HIST1H2A
K;JOSD2;SCAF1;RPS26;HIST1H4A;HIST3H2A;HIST1H4B;COL2A1;HIST4H4;GNB2;CROCC;H
IST1H2BH;ATP13A2;HIST1H2BG;HIST1H4C;PCNXL3;HIST1H4D;PPP1R12C;CSNK1G2;C2CD
2L;HIST1H2BC;HIST1H4F

IRF3_HELAS3

0.000419177

HIST1H2BN;HIST1H2BM;HIST1H2AK;HIST2H2AC;HIST1H4A;HIST1H3A;HIST3H2A;HIST1H
3F;HIST1H3G;HIST1H2BH;HIST1H2BG;HIST1H4C;HIST1H3B;PCNXL3;HIST1H3C;HIST1H3D
;HIST1H2BC;HIST1H1C

MEF2A_K56
2

0.000984914

P300_H1

0.001381286

INTS1;TMEM132A;CCDC124;JOSD2;SCAF1;HIST2H2AC;HIST1H4A;HIST1H4B;HIST4H4;GN
B2;HIST1H4H;RPLP2;HIST1H3I;CKB;HIST1H4C;HIST1H3B;PCNXL3;HIST1H4D;PPP1R12C;C
SNK1G2;HIST1H4F;HIST1H3E

RXRA_GM12
878

0.001381286

HIST1H2BM;INTS1;CCDC124;JOSD2;SCAF1;HIST2H2AC;HIST1H4B;HIST4H4;GNB2;HIST1H
3F;HIST1H4H;HIST1H2BH;HIST1H4C;HIST1H4D

NF-YB_K562

0.001381286

HIST1H2BN;HIST1H2BM;HIST2H2AC;HIST1H3A;HIST1H1D;HIST1H3F;RPLP2;HIST1H3G;C
KB;HIST1H3I;HIST1H3B;HIST1H3C;HIST1H3D;HIST1H1C;HIST1H2AK;NCKAP5L;JOSD2;RPS
26;HIST1H4A;HIST3H2A;GNB2;HIST1H2BH;HIST1H2BG;PCNXL3;HIST1H2BC

GTF2B_K562

0.001718723

HIST1H2BN;HIST2H2AC;RPPH1;HIST1H3A;HIST1H1D;RPL36;RPLP2;HIST1H3B;HIST1H3D;
HIST1H1C;RMRP;INTS1;HIST1H2AK;NCKAP5L;SCAF1;RPS26;HIST1H4A;HIST3H2A;GNB2;
HIST1H4H;HIST1H2BH;HIST1H2BG;HIST1H4D;PPP1R12C;C2CD2L;AHDC1;HIST1H2BC

FOS_GM128
78

0.001922636

HIST1H2BN;HIST1H2BM;HIST1H2AK;HIST3H2A;HIST1H3A;HIST1H3G;HIST1H3I;HIST1H2
BG;HIST1H3B;PCNXL3;HIST1H3C;HIST1H3D;HIST1H2BC

IRF3_GM128
78

0.00274444

HIST1H2BN;HIST1H2BM;HIST1H2AK;HIST2H2AC;HIST1H4A;HIST1H3A;HIST3H2A;GNB2;
HIST1H3F;HIST1H3G;RPLP2;HIST1H2BH;HIST1H3I;HIST1H2BG;HIST1H4C;HIST1H3B;PCN
XL3;HIST1H3C;HIST1H3D;CSNK1G2;HIST1H3E;HIST1H2BC

NRSF_H1

0.00274444

HIST1H2BN;HIST1H2BM;HIST1H3A;HIST4H4;HIST1H2AK;HIST1H4H;HIST1H4C;HIST1H4D
;HIST1H4F;RMRP;HIST2H2AC;HIST1H2BC

JUND_HELAS3

0.00274444

HIST1H2BN;HIST1H2BM;HIST1H4A;RPPH1;HIST1H2AK;HIST1H4H;HIST1H2BG;HIST1H4C;
SCAF1

NFE2_GM12
878

0.00274444

HIST1H2BN;HIST1H2BM;HIST1H2AK;CCDC124;SCAF1;HIST2H2AC;HIST1H4A;RPPH1;HIST
1H4B;HIST4H4;GNB2;HIST1H3I;HIST1H2BG;HIST1H4C;HIST1H3B;PCNXL3;HIST1H3C;HIST
1H3D;HIST1H2BC;RMRP

NFYA_GM1287
8

0.00274444

HIST1H2BN;HIST1H2BM;HIST1H2AK;HIST2H2AC;HIST1H3A;HIST3H2A;HIST1H1D;HIST1H
3F;RPLP2;HIST1H3G;HIST1H2BH;HIST1H3I;HIST1H2BG;HIST1H3B;PCNXL3;HIST1H3C;HIS
T1H3D;HIST1H1C;HIST1H3E;HIST1H2BC

P300_SK-NSH

HIST1H2BN;HIST1H2AK;CKB;HIST1H4D;C2CD2L;HIST1H3D;HIST1H2BC;HIST2H2AC
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HIST1H2BN;HIST1H4A;HIST3H2A;GNB2;HIST1H2AK;HIST1H2BG;HIST1H4C;PCNXL3;HIST
1H4D;HIST1H3D;HIST2H2AC;HIST1H2BC

STAT3_HELA
-S3

0.003883862

TCF12_SK-NSH

0.003883862

SRF_K562

0.004504858

HIST1H2BN;INTS1;HIST1H2AK;CCDC124;JOSD2;SCAF1;RPS26;HIST1H4A;RPPH1;GNB2;P
OLD1;HIST1H4H;RPLP2;ATP13A2;PPP1R12C;CSNK1G2

CJUN_HEPG
2

0.005594011

HIST1H2BN;HIST1H2BM;RPPH1;HIST4H4;HIST1H2AK;CCDC124;HIST1H4H;RPLP2;HIST1H
2BG;HIST1H4C;HIST1H3B;SCAF1

CEBPB_GM1
2878

0.008449704

HIST1H2BN;HIST1H2BM;HIST1H2AK;CCDC124;HIST2H2AC;RPS26;HIST1H4B;HIST3H2A;H
IST4H4;GNB2;HIST1H4H;RPLP2;HIST1H3I;HIST1H2BG;HIST1H3B;PCNXL3;HIST1H4D;HIST
1H3D;HIST1H3E;HIST1H2BC

NF-YA_K562

0.009152463

HIST1H2BN;HIST1H2AK;HIST2H2AC;HIST1H4A;HIST1H3A;HIST3H2A;HIST1H1D;HIST1H3F
;RPLP2;HIST1H2BH;CKB;HIST1H2BG;HIST1H4C;HIST1H3B;PCNXL3;HIST1H3D;HIST1H1C;
HIST1H2BC

BRF2_HELAS3

0.009152463

HIST1H2BN;HIST1H2AK;HIST1H4H;EMILIN1;HIST1H4C;HIST1H3B;HIST1H4D;HIST1H3D

RPPH1;RMRP
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that TDG localizes to a CpG island overlapping with the promoter of CDKN2A and recruits
the co-activator CBP, leading to CDKN2A’s transcription. Importantly, no change in the
methylation status of the CDKN2A promoter was found in TDG depleted IMR90 cells.
Recent work in ESCs found that TDG depletion led to the accumulation of the active
demethylation metabolites 5caC and 5fC. Bisulfite sequencing is unable to identify these
metabolites, which would register the same readout as unmodified cytosines. It is therefore
possible that changes in the metabolite landscape is altered at this site, however further
studies will be needed to investigate this possibility.
While senescence has traditionally been shown to be a response to different forms of
cellular stress, recent work has revealed that the senescence program plays critical roles
during embryonic development in mice (Muñoz-Espín et al., 2013; Storer et al., 2013;
Zhang et al., 2014). To test whether TDG is important during embryonic senescence, I
generated a TDG-HET and TDG-KO mouse and assayed for the senescence marker βgalactosidase during embryonic development. Mice which have depleted TDG show
perturbed staining at structures that undergo senescence. CDKN2A is not expressed during
embryonic development and therefore does not play a role in the establishment of
senescence as it does in adult fibroblasts. This finding is consistent with reports
highlighting that many of the key players in the senescence of differentiated tissue are
likely not drivers of the developmental senescence program (Campisi and D’Adda Di
Fagagna, 2007; Collado et al., 2007). Indeed, investigation into the ectodermal ridge, a
structure which undergoes senescence at approximately E10.5 revealed that while a subset
of known senescence markers were expressed, important markers like p53, p19, or
CDKN2A were not expressed (Storer et al., 2013). Gene-enrichment analysis on the set of
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genes that are differentially regulated between TDG-WT and TDG-KO revealed a
significant enrichment for the categories, “Oxidative Stress Induced Senescence” and
“Senescence Associated Secretory Phenotype”. Closer inspection of the genes which
underlie these subsets finds that the major statistically significant positive hits are due to a
differential expression of histones between the two cohorts. More specifically, histone
transcription of various histones appears to be downregulated in TDG knockout in mice:
of the 66 genes which are downregulated in our TDG knockout mice, 29 (44%) are histones
(Table 3-1). Limited information is available regarding histone dynamics during
senescence. Certain levels of certain histone variants like linker histone H1 have been
shown to decrease during certain forms of senescence, while other variants appear to
decrease (Contrepois et al., 2017; Funayama et al., 2006). Levels of histone marks also
change, but the directionality of the changes is believed to dependent on the ‘type’ of
senescence program initiated (Parry and Narita, 2016). Determining whether histone
dysregulation is important for embryonic senescence will require additional studies in order
to fully understand the significance of these observations.
Observing differences in the expression of senescence-associated terms and proteins, even
though our RNA-Seq was performed on the entire embryo rather than limited to the cells
which undergo differential senescence, suggests that TDG may ‘prime’ cells for
senescence en masse, which allows for cell-type specific factors to drive senescence in
certain structures and not others.

Further work, including RNA-Seq targeted at

differentially senesced structures in TDG-WT and TDG-KO mice is necessary to determine
whether this is indeed the case.
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Taken together our findings are the first to show that TDG is general mediator of
senescence and, importantly, is able to drive senescence through distinct pathways. Indeed,
TDG is one of the few molecules which appear to drive senescence programs in both
development and adult tissue. While manipulation of the senescence program is being
explored as a therapeutic strategy to overcome various pathologies, major hurdles remain.
One of the biggest issues is that the effects of senescence appear to have both beneficial
and/or detrimental effects depending on context. For example, the initiation of senescence
in tumors leads to SASP which recruits the immune system, resulting in tumor regression
and preventing tumor re-growth. Paradoxically, in other cases the initiation of senescence
and SASP, has also been shown to be tumorigenic, increasing the aggressiveness and rate
at which tumors progressed. Whether this is due to a defect in the senescence program, the
immune system, or something else entirely, is not clear. To resolve these sorts of questions
and identify new therapeutic targets, identifying important factors and the context under
which they function will be required.

3.4

Materials and Methods

Cells culture, treatment and transfections
IMR-90 and HFL cells were obtained from ATCC and grown in DMEM supplemented
with 10% Fetal Bovine Serum (FBS). Cell were washed with DMEM and treated with
H2O2 for 2 h at which point they were washed twice and then replaced with DMEM. Stock
H2O2 (30%) was diluted with media to obtain desired concentration/amount prior to
treatment.

siRNA

treatments

were

performed

using

Lipofectamine

2000
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(LifeTechnologies) according to the manufacturer’s instructions. Cells were treated for
siRNA targeting TDG (Dharmacon, M-040666-01) or scrambled siRNA (Dharmacon, D001210-03) for 24h at which point cells were washed once and media was replaced with
fresh DMEM.
Protein extraction and Immunoblotting
Whole cell protein extracts were obtained by harvesting cells in RIPA lysis buffer (50mM
Tris (pH 8) 0.15M NaCl, 1% NP40, 0.5% sodium cholate and 0.1% SDS). Cells were
incubated on ice for 15min and centrifuged for 15 min at 4°C (~20,000 RCF). Protein
concentrations were normalized, and proteins were separated by SDS-PAGE then
transferred to PVDF for 1 hr. The PVDF membrane was placed in blocking buffer
consisting of PBS, 0.1% Tween-20 and 5% skim milk powder which was also used for
primary and secondary incubation as well as washes. All secondary antibodies used are
conjugated to horseradish peroxidase (HRP). To visualize proteins, chemiluminescence
film (Anersgan Hyperfilm ECL) was exposed to membranes treated for 5min with
Luminata Forte Western HRP Substrate (Cat. No. WBLUF0100).
ChIP and analysis
IMR90 cells were transfected with siRNA targeting TDG or control siRNA for 3 d at which
point they were treated with H2O2 for the time specified. ChIP was performed using a
polyclonal affinity purified TDG antibody (Thermo Fisher Cat. PA5-29140) or with a CBP
antibody (Santa Cruz (A-22): sc-369), as previously described, with minor alterations
(Thillainadesan et al., 2012). Briefly, cells were cross-linked using 1% formaldehyde in
PBS for 10 min under shaking at RT. 0.125 mM glycine in PBS was then added for 5min
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to quench the reaction. Cells were then washed twice with ice-cold PBS and harvested in
1 ml of ice cold PBS buffer. The cells were then pelleted at 250g for 10 minutes, washed
twice with ice-cold PBS (protease inhibitors added), and then lysed using 200 μl of lysis
buffer (1% SDS, 50 mM Tris-HCl [pH 8.0], 10 mM EDTA, and protease inhibitors) for 15
minutes on ice. The cell lysates were then sonicated and cell lysate was centrifuged at
15000 rpm for 15 minutes. An aliquot of the supernatant mixture was saved as input DNA,
and the remaining lysate was incubated with 5 ug of antibody in 50 μl of protein A/G
dynabeads as per instructions. ChIP was performed overnight at 4°C under rotation. The
dynabeads were then washed twice with wash buffer I (0.1 % SDS, 1 % Triton X-100, 2
mM EDTA, 20 mM Tris-HCl [pH 8.0], 150 mM NaCl), once with wash buffer II (0.1 %
SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.0], 500 mM NaCl), and
then with wash buffer III (0.25 M LiCl, 1% NP-40, 1% Na-deoxycholate, 1 mM EDTA,
10 mM Tris-HCl [pH 8.0]) and twice with Tris-EDTA buffer (pH 8.0). The chromatin was
eluted using 150 μl of freshly made elution buffer I (1% SDS, 0.1 M NaHCO3) twice at
65°C for 10 minutes. NaCl was added to the eluates and to input DNA to a final
concentration of 0.3 M and both were incubated at 65°C overnight. Immunoprecipitated
DNA was purified using QIAquick PCR Purification Kit (Qiagen) and was analyzed by
quantitative PCR with the indicated primers, or run on a gel, in technical triplicates and
biological duplicates, unless otherwise noted. Primers used for promoter of CDKN2A:
CDKN2A-ChIP-FORWARD: CTGTCCCTCAAATCCTCTGG
CDKN2A-ChIP-REVERSE: ATTCGCTAAGTGCTCGGAGT
Bisulfite sequencing

162

DNA was extracted from IMR90 cells using Sigma’s Genomic DNA extraction kit. DNA
was bisulfite-converted using EpiTect Bisulfite Kit (QIAGEN), according to
manufacturer’s instructions. Primers used for bisulfite sequencing:
CDKN2A-BS-Forward: GTTGGTAAGGAAGGAGGATTGG
CDKN2A-BS-Reverse: CTCTCCAAAAAAAATCCTTTAAAC

β-galactosidase staining
In vitro and in vivo β-galactosidase staining of IMR90 or HFL-1 cells and embryos, was
done as previously described (Dimri et al., 1995; Keyes et al., 2005) with alterations.
Briefly, after treatments media was removed and cells were washed twice with PBS then
fixed with 0.2% glutaraldehyde for 5 minutes after which cells were again washed with
PBS, and then treated with the staining mix composed of: 1mg/ml X-gal (Wisent), 150 mM
NaCl, 2mM MgCl2, 5mM K3Fe(CN)6, 5mM K4Fe(CN)6, 40mM NaPi (Sodium phosphate
buffer). Cells were kept at 37C for 20 hr prior to visualization.
Mouse Protocol
All mouse experiments were done in compliance with the Institutional Animal Care and
Use Committee guidelines at London Regional Cancer Center at Western University and
the University of British Columbia. To generate Tdg knockout mice, Tdg

fl/fl

mice were

bred with C57BL/6 Cre-deleter mice which excise loxP flanked regions and generated the
Tdg heterozygous constitutive knock-out mice. These Tdg heterozygous constitutive
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knock-out mice were bred to create the range of genotypes used for the embryonic
senescence staining assay.
Adult (8 weeks old) UBC-cre/ERT2; Tdgfl/fl and litter matched Tdgfl/fl controls were
intraperitoneally injected with 3 mg TAM daily for 5 days. To assess cre-ERT2 efficiency,
the mice were euthanized 4 weeks after TAM injections, tissues were harvested, lysed
using RIPA buffer and western blotting performed using an anti-TDG-antibody.
RNA-Seq and analysis
Sample quality control was performed using the Agilent 2100 Bioanalyzer. Qualifying
samples were then prepped following the standard protocol for the NEBnext Ultra ii
Stranded mRNA (New England Biolabs). Sequencing was performed on the Illumina
NextSeq 500 with Paired End 42bp × 42bp reads. De-multiplexed read sequences were
then aligned to the Mus Musculous (mm10) reference sequence using STAR
(https://www.ncbi.nlm.nih.gov/pubmed/23104886) aligner. Assembly and differential
expression was estimated using Cufflinks (http://cole-trapnell-lab.github.io/cufflinks/)
through bioinformatics apps available on Illumina Sequence Hub. Prior to down-stream
analysis, list of differentially expressed genes was filtered to remove genes on X and Y
chromosomes to avoid sex bias. Pathway analysis was performed using Reactome Pathway
Database (http://reactome.org) using default parameters. Integrative Genomics Viewer
(IGV) was used for viewing high-throughput data-files.
Western Blot quantification was done using ImageJ software and default parameters
(https://imagej.nih.gov/ij/).
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4.1

Overview

While TDG has been previously implicated in playing a role in ERα signaling, information
regarding the specifics of its role have been limited. To extend the role of TDG in ERα
signaling, I performed a ChIP-Seq using an antibody targeting TDG in MCF7 cells -/+ E2,
followed by bioinformatic analysis and conventional assays. I found TDG was required
for β-estradiol induction of certain ERα target genes. Investigation into the mechanism
through which TDG exerts its effects revealed that, in response to β-estradiol, TDG
localizes predominantly to distal regulatory regions in ERα target genes. Bioinformatic
analysis revealed that these regions are bonafide enhancers and occupied by proteins
important to enhancer function, including CBP/p300, ERα and RNA Pol II. Using
conventional biochemical methods in conjunction with recently developed techniques, I
discovered that TDG is important for both the transcription of long non-coding enhancer
RNA from targeted enhancers, as well as the 3-dimensional reorganization that brings
together the enhancer with the associated promoter of some target genes. Depletion of TDG
resulted in disruption of eRNA production, looping and target-gene transcription. Taken
together this work extends the role of TDG in ERα signaling and also uncovers a previously
unknown role for TDG: as a regulator of eRNA transcription.
In the context of senescence, I discovered that TDG is required for cells to mount a proper
senescence response to oxidative stress in the form of H2O2.

Using conventional

biochemical methods along with ChIP and bisulfite sequencing I found that TDG mediates
its effects by upregulating CDKN2A-induction. Importantly, TDG depletion did not result
in changes in the methylation status of the CDKN2A promoter, suggesting that its impact
is independent of its ability to act in the active demethylation pathway. Indeed, ChIP
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performed using a CBP-specific antibody found that TDG is required for the recruitment
of CBP to the CDKN2A promoter region, suggesting it is its role as a scaffold, rather than
a mediator of active demethylation, that is responsible for activating CDKN2A expression.
In addition to senescence in adult tissue, I sought to investigate whether TDG played a role
in the senescence program initiated during embryonic development. RNA-Seq on whole
mount embryos, either wild-type or TDG-KO, revealed that TDG deletion resulted in
defects in the developmental senescence program through a CDKN2A-independent
mechanism. Gene enrichment analysis comparing TDG-WT to TDG-KO mice revealed
alterations to transcript levels of genes important for “Cellular response to stress”,
“Oxidative Stress Induced Senescence” and “Senescence-Associated Secretory Phenotype
(SASP)” and showed that WNT and Hedgehog pathways may be impacted. Taken together
this work provides the first evidence that TDG plays a role in both adult and embryonic
senescence programs.

TDG’s effects as an oncogene and tumor
suppressor.

4.2

The question as to whether TDG is an oncogene or tumor suppressor remains elusive.
TDG’s ability to repair mismatches and improperly modified cytosines suggests that
knockout of TDG should result in increased mutations throughout the genome. Knockout
studies performed in mouse model systems have found that deletion of MBD4, the
functional homologue of TDG, resulted in increased C:T mutations, as well as increased
tumorigenic potential when MBD4 knockout mice are bred with mice predisposed to colon
cancer (Wong et al., 2002). Furthermore, TDG functions as a co-activator for the
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transcriptional activation of a variety of tumor suppressors, including CDKN2B, p21, p53,
CDKN2A, and HIC1 (Hassan et al., 2017; Kim and Um, 2008; Thillainadesan et al., 2012).
Collectively, this suggests that TDG may behave as a tumor suppressor and its silencing or
mutation should be found in cancer. However, a survey of online databases, including
TCGA, finds that TDG mutation or silencing does not appear to be wide-spread. Several
interesting observations however may explain this apparent discrepancy: Firstly, knockout
studies of TDG found no increase in mutation load compared to wild-type mice, suggesting
that functional redundancy compensates for any deficiencies in mutation repair imposed
by TDG deletion (Cortázar et al., 2011; Cortellino et al., 2011). Secondly, whatever antitumor effects TDG may exert through its control of tumor suppressors or otherwise, must
be weighed against any pro-selection advantages it may offer. In the case of breast cancer,
I found that depletion or knockout negatively impacts ERα signaling, which is reflected in
the blunted response to estradiol-mediated induction of ERα target-genes and decreased
proliferation in MCF7 cells. ERα signaling is a key component of early breast cancer
development and so it stands to reason that cells with a loss of TDG, which mediates ERα
signaling, are likely selected against during tumour development. Similar observations
have been made in other systems as well. For example, in Wnt-driven colorectal cancer,
the authors found that TDG was required for the upregulation of Wnt targets and drove
cancer.

Furthermore,

no homozygous mutations for TDG are observed in CRC –

supporting the idea that the presence of TDG is required for the establishment of the cancer
in the first place, which ‘protects’ it from being silenced, even at the expense of tumors
retaining the ability to repair mismatched nucleotides, or activate tumor suppressors (Xu
et al., 2014).
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Additionally, context appears to be a critical determinant of whether TDG acts as a tumor
suppressor or oncogene. For example, a conditional knockout of TDG in the intestinal and
colonic epithelium of APCMin mice (i.e. mice predisposed to intestinal adenoma formation)
results in significantly higher rates of tumor formation in TDG-KO mice as compared to
the controls (Xu et al., 2017). Estrogen plays a protective role in colorectal cancers, with
increased rates of tumor formation in females who have undergone an ovariectomy (Xu et
al., 2017). Comparing the results of ovariectomies in control mice vs TDG conditional
knockouts, researchers found that, in contrast to the findings that TDG is a driver of
colorectal cancer by upregulating Wnt signaling, the protective role of estrogen is likely to
be largely TDG-dependent, supporting a role for TDG as a tumor suppressor. Collectively
these findings reflect similar dynamics that are observed in breast cancer where TDG
mediates both pro- and anti-tumor effects, further highlighting its pleiotropic nature.

4.3

TDG functions as a scaffold

In my investigation into TDG’s role in ER-signaling in breast cancer as well as its role in
senescence, I found no evidence for active demethylation when TDG is engaged. More
specifically, in both ERα signaling and senescence, I found that TDG localizes to
hypomethylated regions. In the case of senescence, I investigated the methylation status
of the CDKN2A promoter, to determine whether depletion of TDG resulted in its
hypermethylation and silencing of CDKN2A expression. While TDG depletion did result
in reduced CDKN2A levels, this was not accompanied by changes in methylation with the
promoter remaining in a hypomethylated state.

Instead, I found TDG-dependent
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localization of CBP to the CDKN2A promoter upon H2O2 treatment. Importantly, TDG
depletion prior to H2O2 treatment significantly attenuates the recruitment of CBP,
consistent with other reports that find that TDG acts as a scaffold, recruiting, among other
important transcription factors, CBP (Chen et al., 2003; Tini et al., 2002). While this isn’t
always the case (TDG’s glycosylase activity has also been shown to be critical to retinoic
acid signaling for example), it appears that TDG’s scaffolding capability is more general
and is required in order to stabilize necessary complexes to activate transcription, while its
glycosylase activity may only be necessary when removal of DNA methylation is required.
In the context of ER-signaling, I found that TDG localizes to enhancers which were
hypomethylated. Therefore, I examined the consequences of TDG knock down at two
ER/TDG targeted enhancers (TFF1 and GREB1) using bisulfite sequencing. Interestingly,
I found no change in the methylation status of these enhancers, which was not entirely
unexpected as previous reports showed that TDG knockout in mouse embryonic stem cells
results in the accumulation of active-demethylation metabolites, rather than outright
methylation (Raiber et al., 2012; Shen et al., 2013). To interrogate changes to active
demethylation metabolites during TDG depletion, I used MAB-Seq. Remarkably, I found
that regions bound by TDG are composed almost entirely of unmodified cytosines, and this
remained unchanged regardless of E2 treatment and/or TDG depletion. While the lack of
methylation at these sites explains why there is no accumulation of active demethylation
metabolites in the absence of TDG (methylation must be present in order for active
demethylation metabolites to accumulate), it is not clear as to what is preventing DNMT
mediated methylation of these specific site yet allowing it to occur at other sites throughout
the genome.

190

4.4

Future Directions

During the course of my investigations, I discovered that TDG plays a critical role in H2O2induced senescence in human fibroblasts and during development. I found that TDG drives
H2O2-induced senescence likely through the recruitment of coactivator CBP to the
CDKN2A promoter. Importantly, while TDG appears to be important for developmental
senescence, this occurs independent of CDKN2A, which is not expressed in either TDGWT or TDG-KO mice. Whole-mount RNA-Seq comparing TDG-KO and TDG-WT mice
identified differentially expressed genes between the two cohorts, and gene enrichment
highlighted dysregulated pathways which may be responsible for the observed defects.
One concern with whole mount RNA-Seq is that it may mask subtle but critical differences
that are limited to specific structures that undergo senescence.

It will therefore be

important to conduct an RNA-Seq on a structure (ex. the apical ecto-dermal ridge) that
undergoes differential senescence in TDG-KO vs TDG-WT mice to formally identify
genes which are dysregulated upon TDG knockout and which may therefore contribute to
defects in embryonic senescence.
While senescent cells have classically been characterized according to phenotypic traits
and molecular markers, it has become increasingly clear that cellular senescence can take
on many distinct forms depending on cell type as well as the stressors involved in inducing
the senescence program. As therapeutic approaches are being developed and tested,
classifying different forms of senescence will be important when seeking to effectively
target treatments.

The role of TDG in H2O2-induced senescence and in embryonic
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senescence, appears to involve distinct pathways. This suggests that TDG may underlie
other forms of senescence as well. A comprehensive survey of the literature to identify
different forms of senescence in conjunction with siRNA mediated TDG depletion studies
can answer whether or not this is the case. A resource such as this would not only help
characterize senescence (helping to establish whether certain proteins or pathways underlie
senescence in a general sense or identify critical differences between different senescence
programs) but would be useful for identifying new therapeutic targets.
During my research into estrogen signaling I uncovered a novel role of TDG in gene
transcription, finding that in response to β-estradiol, TDG mediates the transcription of
eRNA from enhancers of ERα target genes. Depleting cells of TDG not only inhibited the
transcription of the eRNA’s, but also inhibited the transcription of the primary transcripts
themselves. Furthermore, eRNA per se has been shown to mediate 3-dimensional reorganization at ERα target genes (Li et al., 2013). I confirmed that TDG depletion not only
leads to a loss of eRNA production but ablates the 3-dimensional re-organization important
for bringing into proximity the promoter, enhancer and all of the transcriptional machinery
that resides on both regulatory regions, at the ERα target GREB1. While I found that TDG
regulates the production of eRNA from specific enhancers and mediates looping at one of
these targets, it is currently unclear how prevalent this is in ERα signaling. To obtain a
better understanding of the importance of TDG in ERα signaling, one can use RNA-Seq
which gives an accounting of global transcript levels, in conjunction with siRNA-mediated
knockdown studies. Alternatively, global run-on sequencing (GRO-Seq) can be used which
accurately depicts nascent transcription, to determine the global role of TDG in both eRNA
transcription as well as mRNA transcription. In conjunction with insight into how TDG
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alters transcription of eRNA and mRNA, tools and technologies such as chromatin
conformation capture sequencing (Hi-C) would allow us to determine 3-dimensional
chromosome organization and how TDG impacts changes. Integrating this new data with
our ChIP-Seq, would provide a detailed overview the role of TDG in ERα signaling.
Interestingly, in many studies approximately the same number of genes are repressed upon
E2 treatment as are activated (Osmanbeyoglu et al., 2013). The mechanism through which
repression occurs is not clear. However recent work has revealed 3-dimensional
reorganization may govern E2-mediated repression (Osmanbeyoglu et al., 2013).
Importantly, E2 treatment in MCF7 cells disrupts the 3-dimensional organization at a
subset of genes, leading to their repression, while concurrently establishing 3-dimensional
contacts at a new set of genes that then become actively transcribed. The role of enhancers
and enhancer RNA has not been investigated in the E2-mediated repression of genes,
however it seems plausible that the mechanisms that govern formation of 3-dimensional
organization in response to E2 treatment at E2 inducible genes also govern the transcription
of E2-repressed genes, prior to E2 treatment. Whether TDG plays a role in E2-mediated
repression is unknown. To explore the possibility that TDG mediates E2-repression it may
be worthwhile to compare our ChIP-Seq data with available datasets in order to establish
TDG whether TDG is present at sites which are actively transcribed and then become
repressed in response to E2.
Another question that is raised by my work is whether TDG’s role at enhancers extends to
other signaling pathways such as, TGF-β signaling, RAR-signaling. Indeed, recent work
by our lab in retinoic acid signaling observed that in response to retinoic acid, TDG
activated transcription of HIC1, an RAR-target gene, through 3-dimensional re-
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organization bringing together a distal element with the promoter (Hassan et al., 2017).
Whether eRNA production from the distal region mediates this interaction and what role,
if any, TDG plays in these dynamics has not been investigated. In HaCat cells for example,
TDG activates CDKN2B in response to TGF-β through the active demethylation of the
CDKN2B promoter (Thillainadesan et al., 2012). Importantly, loss of TDG results in
repression of the promoter and an inability to activate CDKN2B in response to TGF-β.
Extending these results globally, using ChIP-Seq, found that that the demethylation of the
CDKN2B promoter is unique, as the majority of the overlap between TDG binding and
demethylation in response to TGF-β actually occurs intergenically, outside of annotated
promoters. In light of recent findings that TDG mediates transcription or active
demethylation at enhancers, it would be interesting to explore dynamics at these distal sites
in HaCat cells that undergo TDG binding and demethylation. Unlike enhancers in MCF7
cells which are hypomethylated prior to TDG localization, distal sites in HaCat cells are
methylated and, concurrent with TDG binding, undergo demethylation. Whether these are
enhancer sites that produce eRNA and undergo 3-dimensional reorganization remains to
be explored. If these sites are bonafide enhancers, they will provide us with an ideal system
to explore the role of TDG-mediated active demethylation at enhancers: determining if its
required for coregulator recruitment, eRNA production and 3-dimensional reorganization.
Finally, a key finding of my work was the observation that in the MCF7 breast cancer cell
line, TDG has both pro- and anti-tumor functionality: mediating ERα signaling while
limiting migration and invasiveness. In the pursuit of identifying therapeutic targets, this
mutually-opposed pleiotropy poses an interesting challenge, namely, identifying in what
contexts inhibition of TDG may prove to be potentially therapeutic. While empirical tests
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employing a wide variety of cell-lines and/or human tissues may be helpful, a global
accounting of transcription profiles using RNA-Seq across a wide range of samples can
expose which targets of TDG are down-regulated during TDG silencing, allowing for the
development of ‘markers’ than can indicate under which circumstances targeting TDG can
be effective.
Collectively, this body of work has expanded our knowledge regarding the mechanism
through which TDG functions and extended its role to senescence in adult tissue and
embryonic development. Future work extending from this research offers an exciting
possibility to deepen our understanding of early transcriptional events that are often
dysregulated in various human pathologies and as such may open new targets for
therapeutic intervention.
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